Efflux-mediated antimicrobial resistance

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 20-51

  Poole, Keith ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Antibiotics; Antimicrobials; Biocides; Efflux; Multidrug; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BIOCIDE; CHLORAMPHENICOL; CHLORTETRACYCLINE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN; ERYTHROMYCIN; FLORFENICOL; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LINCOMYCIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; MINOCYCLINE; NORFLOXACIN; OXAZOLIDINONE DERIVATIVE; OXYTETRACYCLINE; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; STREPTOGRAMIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG; VIRGINIAMYCIN; AMINOGLYCOSIDE; QUINOLONE DERIVATIVE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL MUTATION; GRAM NEGATIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTEGRON; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; REGULATOR GENE; REVIEW; SIDE EFFECT; STREPTOMYCES; TRANSPOSON; TRANSPORT AT THE CELLULAR LEVEL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CHLORAMPHENICOL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; TETRACYCLINE;

EID: 24044514016     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki171     Document Type: Review

References (578)

1. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. [i#Nature#1i] 1940; [b#146#1b]: 837-9.
2. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. [i#Nat Med#1i] 2004; [b#10#1b]: S122-29.
3. Howell-Jones RS, Wilson MJ, Hill KE [i#et al.#1i] A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. [i#J Antimicrob Chemother#1i] 2005; [b#55#1b]: 143-9.
4. Finch RG. Antibiotic resistance: A view from the prescriber. [i#Nat Rev Microbiol#1i] 2004; [b#2#1b]: 989-94.
5. Smith SV, Gould IM. Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance. [i#Expert Rev Anti Infect Ther#1i] 2004; [b#2#1b]: 227-34.
6. Pong A, Bradley JS. Clinical challenges of nosocomial infections caused by antibiotic-resistant pathogens in pediatrics. [i#Semin Pediatr Infect Dis#1i] 2004; [b#15#1b]: 21-9.
7. Bronzwaer S, Lonnroth A, Haigh R. The European Community strategy against antimicrobial resistance. [i#Euro Surveill#1i] 2004; [b#9#1b]: 1-3.
8. Mutnick AH, Rhomberg PR, Sader HS [i#et al.#1i] Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 290-6.
9. Jain R, Danziger LH. Multidrug-resistant [i#Acinetobacter infections#1i]: an emerging challenge to clinicians. [i#Ann Pharmacother#1i] 2004; [b#38#1b] 1449-59.
10. Du B, Long Y, Liu H [i#et al.#1i] Extended-spectrum β-lactamase-producing [i#Escherichia coli#1i] and [i#Klebsiella pneumoniae#1i] bloodstream infection: Risk factors and clinical outcome. [i#Intensive Care Med#1i] 2002; [b#28#1b]: 1718-23.
11. Blot SI, Vandewoude KH, Hoste EA [i#et al.#1i] Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant [i#Staphylococcus aureus. Arch Intern Med#1i] 2002; [b#162#1b]: 2229-35.
12. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant [i#Staphylococcus aureus#1i] infections. [i#Ann Pharmacother#1i] 2004; [b#38#1b]: 1377-82.
13. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal blood-stream infection. [i#J Infect Dis#1i] 2005; [b#191#1b]: 588-95.
14. Overbye KM, Barrett JF. Antibiotics: Where did we go wrong? [i#Drug Discov Today#1i] 2005; [b#10#1b]: 45-52.
15. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. [i#Clin Infect Dis#1i] 2003; [b#36#1b]: 1433-7.
16. Watters K, O'Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: What are the consequences? [i#J Laryngol Otol#1i] 2004; [b#118#1b]: 694-9.
17. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. [i#Crit Care Med#1i] 2001; [b#29#1b]: N114-N120.
18. Engemann JJ, Carmeli Y, Cosgrove SE [i#et al.#1i] Adverse clinical and economic outcomes attributable to methicillin resistance among patients with [i#Staphylococcus aureus#1i] surgical site infection. [i#Clin Infect Dis#1i] 2003; [b#36#1b]: 592-8.
19. Toubes E, Singh K, Yin D [i#et al.#1i] Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: Does antimicrobial choice make a difference? [i#Clin Infect Dis#1i] 2003; [b#36#1b]: 724-30.
20. Kollef MH. Gram-negative bacterial resistance: Evolving patterns and treatment paradigms. [i#Clin Infect Dis#1i] 2005; [b#40#1b] Suppl 2: S85-8.
21. Harbarth S, Garbino J, Pugin J [i#et al.#1i] Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. [i#Am J Med#1i] 2003; [b#115#1b] 529-35.
22. Lodise TP, McKinnon PS, Swiderski L [i#et al.#1i] Outcomes analysis of delayed antibiotic treatment for hospital-acquired [i#Staphylococcus aureus#1i] bacteremia. [i#Clin Infect Dis#1i] 2003; [b#36#1b]: 1418-23.
23. Masterton R, Drusano G, Paterson DL [i#et al.#1i] Appropriate antimicrobial treatment in nosocomial infections - the clinical challenges. [i#J Hosp Infect#1i] 2003; [b#55#1b] Suppl 1: 1-12.
24. Osmon S, Ward S, Fraser VJ [i#et al.#1i] Hospital mortality for patients with bacteremia due to [i#Staphylococcus aureus#1i] or [i#Pseudomonas aeruginosa. Chest#1i] 2004; [b#125#1b]: 607-16.
25. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. [i#J Appl Microbio1#1i] 2002; [b#92#1b] Suppl 1: 55S-64S.
26. Wright GD. Mechanisms of resistance to antibiotics. [i#Curr Opin Chem Biol#1i] 2003; [b#7#1b]: 563-9.
27. McDermott PF, Walker RD, White DG. Antimicrobials: Modes of action and mechanisms of resistance. [i#Int J Toxicol#1i] 2003; [b#22#1b]: 135-43.
28. Hogan D, Kolter R. Why are bacteria refractory to antimicrobials? [i#Curr Opin Microbiol#1i] 2002; [b#5#1b]: 472.
29. Normark BH, Normark S. Evolution and spread of antibiotic resistance. [i#J Intern Med#1i] 2002; [b#252#1b]: 91-106.
30. Davies D. Understanding biofilm resistance to antibacterial agents. [i#Nat Rev Drug Discov#1i] 2003; [b#2#1b]: 114-22.
31. Gilbert P, Maira-Litran T, McBain AJ [i#et al.#1i] The physiology and collective recalcitrance of microbial biofilm communities. [i#Adv Microb Physiol#1i] 2002; [b#46#1b]: 202-56.
32. Drenkard E. Antimicrobial resistance of [i#Pseudomonas aeruginosa#1i] biofilms. [i#Microbes Infect#1i] 2003; [b#5#1b]: 1213-9.
33. Fux CA, Costerton JW, Stewart PS [i#et al.#1i] Survival strategies of infectious biofilms. [i#Trends Microbiol#1i] 2005; [b#13#1b]: 34-40.
34. Roberts ME, Stewart PS. Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. [i#Microbiology#1i] 2005; [b#151#1b]: 75-80.
35. Wattanakaroon W, Stewart PS. Electrical enhancement of [i#Streptococcus gordonii#1i] biofilm killing by gentamicin. [i#Arch Oral Biol#1i] 2000; [b#45#1b]: 167-71.
36. Borriello G, Werner E, Roe F [i#et al.#1i] Oxygen limitation contributes to antibiotic tolerance of [i#Pseudomonas aeruginosa#1i] in biofilms. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 2659-64.
37. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. [i#Drugs#1i] 2004; [b#64#1b]: 159-204.
38. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. [i#Biochem J#1i] 2003; [b#376#1b]: 313-38.
39. Chang G. Multidrug resistance ABC transporters. [i#FEBS Lett#1i] 2003; [b#555#1b]: 102-5.
40. Lage H. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 188-99.
41. Mazurkiewicz P, Driessen AJ, Konings WN. What do proton motive force driven multidrug resistance transporters have in common? [i#Curr Issues Mol Biol#1i] 2005; [b#7#1b]: 7-21.
42. McMurry LM, Petrucci RE, Jr, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in [i#Escherichia coli. Proc Natl Acad Sci USA#1i] 1980; [b#77#1b]: 3974-7.
43. Ball PR, Shales SW, Chopra I. Plasmid-mediated tetracycline resistance in [i#Escherichia coli#1i] involves increased efflux of the antibiotic. [i#Biochem Biophys Res Commun#1i] 1980; [b#93#1b]: 74-81.
44. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. [i#Microbiol Mol Biol Rev#1i] 2000; [b#64#1b]: 672-93.
45. Poole K. Multidrug resistance in Gram-negative bacteria. [i#Curr Opin Microbiol#1i] 2001; [b#4#1b]: 500-8.
46. Colmer JA, Fralick JA, Hamood AN. Isolation and characterization of a putative multidrug resistance pump from [i#Vibrio cholerae. Mol Microbiol#1i] 1998; [b#27#1b]: 63-72.
47. Butaye P, Cloeckaert A, Schwarz S. Mobile genes coding for efflux-mediated antimicrobial resistance in Gram-positive and Gram-negative bacteria. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 205-10.
48. Schwarz S, Kehrenberg C, Doublet B [i#et al.#1i] Molecular basis of bacterial resistance to chloramphenicol and florfenicol. [i#FEMS Microbiol Rev#1i] 2004; [b#28#1b]: 519-42.
49. Bissonnette L, Champetier S, Buisson JP [i#et al.#1i] Characterization of the nonenzymatic chloramphenicol resistance [i#(cmlA)#1i] gene of the In4 integron of Tn[i#1696#1i]: Similarity of the product to transmembrane transport proteins. [i#J Bacteriol#1i] 1991; [b#173#1b]: 4493-502.
50. Guerra B, Soto SM, Arguelles JM [i#et al.#1i] Multidrug resistance is mediated by large plasmids carrying a class 1 integron in the emergent [i#Salmonella enterica#1i] serotype [4,5,12:i:-]. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 1305-8.
51. Naas T, Mikami Y, Imai T [i#et al.#1i] Characterization of In53, a class 1 plasmid- and composite transposon-located integron of [i#Escherichia coli#1i] which carries an unusual array of gene cassettes. [i#J Bacteriol#1i] 2001; [b#183#1b]: 235-49.
52. Chang CY, Chang LL, Chang YH [i#et al.#1i] Characterisation of drug resistance gene cassettes associated with class 1 integrons in clinical isolates of [i#Escherichia coli#1i] from Taiwan, ROC. [i#J Med Microbiol#1i] 2000; [b#49#1b]: 1097-102.
53. Partridge SR, Recchia GD, Stokes HW [i#et al.#1i] Family of class 1 integrons related to In4 from Tn[i#1696. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 3014-20.
54. Doublet B, Lailler R, Meunier D [i#et al.#1i] Variant [i#Salmonella#1i] genomic island 1 antibiotic resistance gene cluster in [i#Salmonella enterica#1i] serovar Albany. [i#Emerg Infect Dis#1i] 2003; [b#9#1b]: 585-91.
55. Doublet B, Butaye P, Imberechts H [i#et al. Salmonella#1i] genomic island 1 multidrug resistance gene clusters in [i#Salmonella enterica#1i] serovar Agona isolated in Belgium in 1992 to 2002. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 2510-7.
56. Doublet B, Weill FX, Fabre L [i#et al.#1i] Variant [i#Salmonella#1i] genomic island 1 antibiotic resistance gene cluster containing a novel 3′-N-aminoglycoside acetyltransferase gene cassette, [i#aac(3 -ld#1i], in [i#Salmonella enterica#1i] serovar Newport. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3806-12.
57. Bischoff KM, White DG, Hume ME [i#et al.#1i] The chloramphenicol resistance gene [i#cmlA#1i] is disseminated on transferable plasmids that confer multiple-drug resistance in swine [i#Escherichia coli. FEMS Microbiol Lett#1i] 2005; [b#243#1b]: 285-91.
58. Gebreyes WA, Thakur S. Multidrug-resistant [i#Salmonella enterica#1i] serovar Muenchen from pigs and humans and potential interserovar transfer of antimicrobial resistance. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 503-11.
59. Bischoff KM, White DG, McDermott PF [i#et al.#1i] Characterization of chloramphenicol resistance in β-hemolytic [i#Escherichia coli#1i] associated with diarrhea in neonatal swine. [i#J Clin Microbiol#1i] 2002; [b#40#1b]: 389-94.
60. Boyd D, Cloeckaert A, Chaslus-Dancla E [i#et al.#1i] Characterization of variant [i#Salmonella#1i] genomic island 1 multidrug resistance regions from serovars Typhimurium DT104 and Agona. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 1714-22.
61. CMY-2 genes in [i#Salmonella enterica#1i] serovars Typhimurium and Newport isolated in the United States. [i#FEMS Microbiol Lett#1i] 2004; [b#233#1b]: 301-5.
62. Randall LP, Cooles SW, Osborn MK [i#et al.#1i] Antibiotic resistance genes, integrons and multiple antibiotic resistance in thirty-five serotypes of [i#Salmonella enterica#1i] isolated from humans and animals in the UK. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 208-16.
63. Iwanaga M, Toma C, Miyazato T [i#et al.#1i] Antibiotic resistance conferred by a class I integron and SXT constin in [i#Vibrio cholerae#1i] O1 strains isolated in Laos. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 2364-9.
64. White DG, Hudson C, Maurer JJ [i#et al.#1i] Characterization of chloramphenicol and florfenicol resistance in [i#Escherichia coli#1i] associated with bovine diarrhea. [i#J Clin Microbiol#1i] 2000; [b#38#1b]: 4593-8.
65. Du X, Xia C, Shen J [i#et al.#1i] Characterization of florfenicol resistance among calf pathogenic [i#Escherichia coli. FEMS Microbiol Lett#1i] 2004; [b#236#1b]: 183-9.
66. Sanchez S, McCrackin Stevenson MA, Hudson CR [i#et al.#1i] Characterization of multidrug-resistant [i#Escherichia coli#1i] isolates associated with nosocomial infections in dogs. [i#J Clin Microbiol#1i] 2002; [b#40#1b]: 3586-95.
67. Keyes K, Hudson C, Maurer JJ [i#et al.#1i] Detection of florfenicol resistance genes in [i#Escherichia coli#1i] isolated from sick chickens. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 421-4.
68. Singer RS, Patterson SK, Meier AE [i#et al.#1i] Relationship between phenotypic and genotypic florfenicol resistance in [i#Escherichia coli. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 4047-9.
69. Cabrera R, Ruiz J, Marco F [i#et al.#1i] Mechanism of resistance to several antimicrobial agents in [i#Salmonella#1i] clinical isolates causing traveler's diarrhea. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3934-9.
70. Kehrenberg C, Schwarz S. [i#fexA#1i], a novel [i#Staphylococcus lentus#1i] gene encoding resistance to florfenicol and chloramphenicol. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 615-8.
71. Kehrenberg C, Schwarz S. Florfenicol-chloramphenicol exporter gene [i#fexA#1i] is part of the novel transposon Tn[i#558. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 813-5.
72. George AM, Hall RM. Efflux of chloramphenicol by the CmlA1 protein. [i#FEMS Microbiol Lett#1i] 2002; [b#209#1b]: 209-13.
73. Desomer J, Vereecke D, Crespi M [i#et al.#1i] The plasmid-encoded chloramphenicol-resistance protein of [i#Rhodococcus fascians#1i] is homologous to the transmembrane tetracycline efflux proteins. [i#Mol Microbiol#1i] 1992; [b#6#1b]: 2377-85.
74. Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. [i#Clin Microbiol Infect#1i] 2004; [b#10#1b]: 12-26.
75. Baucheron S, Tyler S, Boyd D [i#et al.#1i] AcrAB-TolC directs efflux-mediated multidrug resistance in [i#Salmonella enterica#1i] serovar typhimurium DT104. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b] 3729-35.
76. Hasdemir UO, Chevalier J, Nordmann P [i#et al.#1i] Detection and prevalence of active drug efflux mechanism in various multidrug-resistant [i#Klebsiella pneumoniae#1i] strains from Turkey. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 2701-6.
77. Chau SL, Chu YW, Houang ET. Novel resistance-nodulation-cell division efflux system AdeDE in [i#Acinetobacter#1i] genomic DNA group 3. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 4054-5.
78. Jalal S, Wretlind G, Gotoh N [i#et al.#1i] Rapid identification of mutations in a multidrug efflux pump in [i#Pseudomonas aeruginosa. APMIS#1i] 1999; [b#107#1b]: 1109-16.
79. Kohler T, Van Delden C, Curty LK [i#et al.#1i] Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in [i#Pseudomonas aeruginosa. J Bacteriol#1i] 2001; [b#183#1b]: 5213-22.
80. Sobel ML, Poole K, Neshat S. Mutations in PA2491 [i#(mexS)#1i] promote MexT-dependent [i#mexEF-oprN#1i] expression and multidrug resistance in a clinical strain of [i#Pseudomonas aeruginosa. J Bacteriol#1i] 2005; [b#187#1b]: 1246-53.
81. Rajyaguru JM, Muszynski MJ. Association of resistance to trimethoprim/ sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in [i#Burkholderia cepacia. J Antimicrob Chemother#1i] 1997; [b#40#1b]: 803-9.
82. Nair BM, Cheung K, Jr, Griffith A [i#et al.#1i] Salicylate induces an antibiotic efflux pump in [i#Burkholderia cepacia#1i] complex genomovar III [i#(B. cenocepacia). J Clin Invest#1i] 2004; [b#113#1b]: 464-73.
83. Burns JL, Wadsworth CD, Barry JJ [i#et al.#1i] Nucleotide sequence analysis of a gene from [i#Burkholderia (Pseudomonas) cepacia#1i] encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. [i#Antimicrob Agents Chemother#1i] 1996; [b#40#1b]: 307-13.
84. Hansen LH, Johannesen E, Burmolle M [i#et al.#1i] Plasmid-encoded multidrug efflux pump conferring resistance to olaquindox in [i#Escherichia coli. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3332-7.
85. Poelarends G, Mazurkiewicz P, Konings W. Multidrug transporters and antibiotic resistance in [i#Lactococcus lactis. Biochim Biophys Acta#1i] 2002; [b#1555#1b]: 1.
86. Olliver A, Valle M, Chaslus-Dancla E [i#et al.#1i] Overexpression of the multidrug efflux operon [i#acrEF#1i] by insertional activation with IS [i#1#1i] or IS[i#10#1i] elements in [i#Salmonella enterica#1i] serovar Typhimurium DT204 [i#acrB#1i] mutants selected with fluoroquinolones. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 289-301.
87. Roberts MC. Tetracycline therapy: Update. [i#Clin Infect Dis#1i] 2003; [b#36#1b]: 462-7.
88. Bartlett JG. [i#2004 Pocket Book of Infectious Disease Therapy#1i], 12 edn. Baltimore: Lippincott Williams & Wilkins, 2004.
89. Roberts MC. Update on acquired tetracycline resistance genes. [i#FEMS Microbiol Lett#1i] 2005; [b#245#1b]: 195-203.
90. Maynard C, Bekal S, Sanschagrin F [i#et al.#1i] Heterogeneity among virulence and antimicrobial resistance gene profiles of extraintestinal [i#Escherichia coli#1i] isolates of animal and human origin. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 5444-52.
91. Butler MJ, Friend EJ, Hunter IS [i#et al.#1i] Molecular cloning of resistance genes and architecture of a linked gene cluster involved in biosynthesis of oxytetracycline by [i#Streptomyces rimosus. Mol Gen Genet#1i] 1989; [b#215#1b]: 231-8.
92. Reynes JP, Calmels T, Drocourt D [i#et al.#1i] Cloning, expression in [i#Escherichia coli#1i] and nucleotide sequence of a tetracycline-resistance gene from [i#Streptomyces rimosus. J Gen Microbiol#1i] 1988; [b#134#1b]: 585-98.
93. Dairi T, Aisaka K, Katsumata R [i#et al.#1i] A self-defense gene homologous to tetracycline effluxing gene essential for antibiotic production in [i#Streptomyces aureofaciens. Biosci Biotechnol Biochem#1i] 1995; [b#59#1b]: 1835-41.
94. Truong-Bolduc QC, Dunman PM, Strahilevitz J [i#et al.#1i] MgrA is a multiple regulator of two new efflux pumps in [i#Staphylococcus aureus. J Bacteriol#1i] 2005; [b#187#1b]: 2395-405.
95. Viveiros M, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b] 274-8.
96. Agersø Y, Guardabassi L. Identification of Tet 39, a novel class of tetracycline resistance determinant in [i#Acinetobacter#1i] spp. of environmental and clinical origin. [i#J Antimicrob Chemother#1i] 2005; [b#55#1b]: 566-9.
97. Poyart C, Jardy L, Quesne G [i#et al.#1i] Genetic basis of antibiotic resistance in [i#Streptococcus agalactiae#1i] strains isolated in a French hospital. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 794-7.
98. Lancaster H, Ready D, Mullany P [i#et al.#1i] Prevalence and identification of tetracycline-resistant oral bacteria in children not receiving antibiotic therapy. [i#FEMS Microbiol Lett#1i] 2003; [b#228#1b]: 99-104.
99. Duarte RS, Bellei BC, Miranda OP [i#et al.#1i] Distribution of antimicrobial resistance and virulence-related genes among Brazilian group B streptococci recovered from bovine and human sources. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 97-103.
100. Nielsen HU, Hammerum AM, Ekelund K [i#et al.#1i] Tetracycline and macrolide co-resistance in [i#Streptococcus pyogenes#1i]: Co-selection as a reason for increase in macrolide-resistant [i#S. pyogenes? Microb Drug Resist#1i] 2004; [b#10#1b]: 231-8.
101. Tian Y, Aarestrup FM, Lu CP. Characterization of [i#Streptococcus suis#1i] serotype 7 isolates from diseased pigs in Denmark. [i#Vet Microbiol#1i] 2004; [b#103#1b]: 55-62.
102. Brenciani A, Ojo KK, Monachetti A [i#et al.#1i] Distribution and molecular analysis of [i#mef#1i](A)-containing elements in tetracycline-susceptible and - resistant [i#Streptococcus pyogenes#1i] clinical isolates with efflux-mediated erythromycin resistance. [i#J Antimicrob Chemother#1i] 2004; [b#54#1b]: 991-8.
103. Matsumoto M, Sakae K, Ohta M [i#et al.#1i] Molecular mechanisms of high level tetracycline-resistance in group A streptococcal isolates, T serotypes 4 and 11. [i#Int J Antimicrob Agents#1i] 2005; [b#25#1b]: 142-7.
104. Rodriguez-Avial I, Rodriguez-Avial C, Culebras E [i#et al.#1i] Distribution of tetracycline resistance genes [i#tet(M), tet(O), tet(L #1i] and [i#tet(K)#1i] in blood isolates of viridans group streptococci harbouring [i#erm(B)#1i] and [i#mef#1i](A) genes. Susceptibility to quinupristin/dalfopristin and linezolid. [i#Int J Antimicrob Agents#1i] 2003; [b#21#1b]: 536-41.
105. Petersen A, Dalsgaard A. Species composition and antimicrobial resistance genes of [i#Enterococcus#1i] spp, isolated from integrated and traditional fish farms in Thailand. [i#Environ Microbiol#1i] 2003; [b#5#1b] 395-402.
106. Huys G, D'Haene K, Collard JM [i#et al.#1i] Prevalence and molecular characterization of tetracycline resistance in [i#Enterococcus#1i] isolates from food. [i#Appl Environ Microbiol#1i] 2004; [b#70#1b]: 1555-62.
107. Ng LK, Martin I, Alfa M [i#et al.#1i] Multiplex PCR for the detection of tetracycline resistant genes. [i#Mol Cell Probes#1i] 2001; [b#15#1b]: 209-15.
108. Strommenger B, Kettlitz C, Werner G [i#et al.#1i] Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in [i#Staphylococcus aureus. J Clin Microbiol#1i] 2003; [b#41#1b]: 4089-94.
109. Sekiguchi J, Fujino T, Saruta K [i#et al.#1i] Prevalence of erythromycin-, tetracycline-, and aminoglycoside-resistance genes in methicillin-resistant [i#Staphylococcus aureus#1i] in hospitals in Tokyo and Kumamoto. [i#Jpn J Infect Dis#1i] 2004; [b#57#1b]: 74-7.
110. Aarestrup FM, Jensen LB. Trends in antimicrobial susceptibility in relation to antimicrobial usage and presence of resistance genes in [i#Staphylococcus hyicus#1i] isolated from exudative epidermitis in pigs. [i#Vet Microbiol#1i] 2002; [b#89#1b]: 83-94.
111. Aarestrup FM, Agers LY, Ahrens P [i#et al.#1i] Antimicrobial susceptibility and presence of resistance genes in staphylococci from poultry. [i#Vet Microbiol#1i] 2000; [b#74#1b]: 353-64.
112. Wilcks A, Andersen SR, Licht TR. Characterization of transferable tetracycline resistance genes in [i#Enterococcus faecalis#1i] isolated from raw food. [i#FEMS Microbiol Lett#1i] 2005; [b#243#1b]: 15-9.
113. Aarestrup FM, Lertworapreecha M, Evans MC [i#et al.#1i] Antimicrobial susceptibility and occurrence of resistance genes among [i#Salmonella enterica#1i] serovar Weltevreden from different countries. [i#J Antimicrob Chemother#1i] 2003; [b#52#1b]: 715-8.
114. Frech G, Schwarz S. Molecular analysis of tetracycline resistance in [i#Salmonella enterica#1i] subsp. enterica serovars Typhimurium, Enteritidis, Dublin, Choleraesuis, Hadar and Saintpaul: Construction and application of specific gene probes. [i#J Appl Microbiol#1i] 2000; [b#89#1b] 633-41.
115. Poppe C, Ziebell K, Martin L [i#et al.#1i] Diversity in antimicrobial resistance and other characteristics among [i#Salmonella typhimurium#1i] DT104 isolates. [i#Microb Drug Resist#1i] 2002; [b#8#1b]: 107-22.
116. Pasquali F, De Cesare A, Ricci A [i#et al.#1i] Phage types, ribotypes and tetracycline resistance genes of [i#Salmonella enterica#1i] subsp. enterica serovar Typhimurium strains isolated from different origins in Italy. [i#Vet Microbiol#1i] 2004; [b#103#1b]: 71-6.
117. Hartman AB, Essiet II, Isenbarger DW [i#et al.#1i] Epidemiology of tetracycline resistance determinants in [i#Shigella#1i] spp. and enteroinvasive [i#Escherichia coli#1i]: Characterization and dissemination of [i#tet(A)-1. J Clin Microbiol#1i] 2003; [b#41#1b]: 1023-32.
118. Toro CS, Farfan M, Contreras I [i#et al.#1i] Genetic analysis of antibiotic-resistance determinants in multidrug-resistant [i#Shigella#1i] strains isolated from Chilean children. [i#Epidemiol Infect#1i] 2005; [b#133#1b]: 81-6.
119. Guerra B, Junker E, Schroeter A [i#et al.#1i] Phenotypic and genotypic characterization of antimicrobial resistance in German [i#Escherichia coli#1i] isolates from cattle, swine and poultry. [i#J Antimicrob Chemother#1i] 2003; [b#52#1b]: 489-92.
120. Sengelov G, Halling-Sorensen B, Aarestrup FM. Susceptibility of [i#Escherichia coli#1i] and [i#Enterococcus faecium#1i] isolated from pigs and broiler chickens to tetracycline degradation products and distribution of tetracycline resistance determinants in [i#E. coli#1i] from food animals. [i#Vet Microbiol#1i] 2003; [b#95#1b]: 91-101.
121. Guardabassi L, Dijkshoorn L, Collard JM [i#et al.#1i] Distribution and in-vitro transfer of tetracycline resistance determinants in clinical and aquatic [i#Acinetobacter#1i] strains. [i#J Med Microbiol#1i] 2000; [b#49#1b]: 929-36.
122. Dugan J, Rockey DD, Jones L [i#et al.#1i] Tetracycline resistance in [i#Chlamydia suis#1i] mediated by genomic islands inserted into the chlamydial [i#inv#1i]-like gene. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3989-95.
123. Wu JY, Kim JJ, Reddy R [i#et al.#1i] Tetracycline-resistant clinical [i#Helicobacter pylori#1i] isolates with and without mutations in 16S rRNA-encoding genes. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 578-83.
124. Gibreel A, Tracz DM, Nonaka L [i#et al.#1i] Incidence of antibiotic resistance in [i#Campylobacter jejuni#1i] isolated in Alberta, Canada, from 1999 to 2002, with special reference to [i#tet(O)#1i]-mediated tetracycline resistance. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b] 3442-50.
125. Turner A, Gough KR, Leeming JP. Molecular epidemiology of [i#tetM#1i] genes in [i#Neisseria gonorrhoeae. Sex Transm Infect#1i] 1999; [b#75#1b]: 60-6.
126. Marquez CM, Dillon JA, Rodriguez V [i#et al.#1i] Detection of a novel Tet M determinant in tetracycline-resistant [i#Neisseria gonorrhoeae#1i] from Uruguay, 1996-1999. [i#Sex Transm Dis#1i] 2002; [b#29#1b]: 792-7.
127. Furushita M, Shiba T, Maeda T [i#et al.#1i] Similarity of tetracycline resistance genes isolated from fish farm bacteria to those from clinical isolates. [i#Appl Environ Microbiol#1i] 2003; [b#69#1b]: 5336-42.
128. Cousin S, Jr, Roberts MC, Whittington WL. Insertion of a thymine (+T) in the 13 base pair inverted repeat of the [i#Neisseria gonorrhoeae mtr#1i] promoter region and antibiotic susceptibility. [i#Int J Antimicrob Agents#1i] 2004; [b#23#1b]: 418-9.
129. De Rossi E, Arrigo P, Bellinzoni M [i#et al.#1i] The multidrug transporters belonging to major facilitator superfamily in [i#Mycobacterium tuberculosis. Mol Med#1i] 2002; [b#8#1b]: 714-24.
130. Ainsa JA, Blokpoel MC, Otal I [i#et al.#1i] Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in [i#Mycobacterium fortuitum#1i] and [i#Mycobacterium tuberculosis. J Bacteriol#1i] 1998; [b#180#1b]: 5836-43.
131. Silva PE, Bigi F, de La Paz SM [i#et al.#1i] Characterization of P55, a multidrug efflux pump in [i#Mycobacterium bovis#1i] and [i#Mycobacterium tuberculosis. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 800-4.
132. Hamzehpour MM, Pechere J-C, Plesiat P [i#et al.#1i] OprK and OprM define two genetically distinct multidrug efflux systems in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 1995; [b#39#1b]: 2392-6.
133. Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in [i#Pseudomonas aeruginosa. Microbiology#1i] 1999; [b#145#1b]: 2857-62.
134. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from [i#Stenotrophomonas maltophilia. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 3079-86.
135. Alonso A, Martinez JL. Multiple antibiotic resistance in [i#Stenotrophomonas maltophilia. Antimicrob Agents Chemother#1i] 1997; [b#41#1b] 1140-2.
136. Zhang L, Li X-Z, Poole K. Multiple antibiotic resistance in [i#Stenotrophomonas maltophilia#1i]: Involvement of a multidrug efflux system. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 287-93.
137. Masuda N, Sakagawa E, Ohya S [i#et al.#1i] Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 2242-6.
138. Goldman RC, Scaglione F. The macrolide-bacterium interaction and its biological basis. [i#Curr Drug Targets Infect Disord#1i] 2004; [b#4#1b]: 241-60.
139. Zhanel GG, Dueck M, Hoban DJ [i#et al.#1i] Review of macrolides and ketolides: Focus on respiratory tract infections. [i#Drugs#1i] 2001; [b#61#1b]: 443-98.
140. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. [i#Clin Infect Dis#1i] 2002; [b#34#1b]: 482-92.
141. Zuckerman JM. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. [i#Infect Dis Clin North Am#1i] 2004; [b#18#1b]: 621-49.
142. Spizek J, Rezanka T. Lincomycin, clindamycin and their applications. [i#Appl Microbiol Biotechnol#1i] 2004; [b#64#1b]: 455-64.
143. Blondeau JM, Sanche SE. Quinupristin/dalfopristin. [i#Expert Opin Pharmacother#1i] 2002; [b#3#1b]: 1341-64.
144. Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. [i#Curr Pharm Des#1i] 2004; [b#10#1b]: 3221-8.
145. Roberts MC. Distribution of macrolide, lincosamide, streptogramin, ketolide and oxazolidinone (MLSKO) resistance genes in Gram-negative bacteria. [i#Curr Drug Targets Infect Disord#1i] 2004; [b#4#1b]: 207-15.
146. Pozzi G, Iannelli F, Oggioni MR [i#et al.#1i] Genetic elements carrying macrolide efflux genes in streptococci. [i#Curr Drug Targets Infect Disord#1i] 2004; [b#4#1b]: 203-6.
147. Roberts MC, Sutcliffe J, Courvalin P [i#et al.#1i] Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2823-30.
148. Klaassen CH, Mouton JW. Molecular detection of the macrolide efflux gene: To discriminate or not to discriminate between mef(A) and mef(E). [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1271-8.
149. Giovanetti E, Brenciani A, Vecchi M [i#et al.#1i] Prophage association of [i#mefA#1i] elements encoding efflux-mediated erythromycin resistance in [i#Streptococcus pyogenes. J Antimicrob Chemother#1i] 2005; [b#55#1b]: 445-51.
150. Daly MM, Doktor S, Flamm R [i#et al.#1i] Characterization and prevalence of MefA, MefE, and the associated [i#msr(D)#1i] gene in [i#Streptococcus pneumoniae#1i] clinical isolates. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 3570-4.
151. Montanari MP, Tili E, Cochetti I [i#et al.#1i] Molecular characterization of clinical [i#Streptococcus pneumoniae#1i] isolates with reduced susceptibility to fluoroquinolones emerging in Italy. [i#Microb Drug Resist#1i] 2004; [b#10#1b]: 209-17.
152. Hotomi M, Yamanaka N, Billal DS [i#et al.#1i] Genotyping of [i#Streptococcus pneumoniae#1i] and [i#Haemophilus influenzae#1i] isolated from paired middle ear fluid and nasopharynx by pulsed-field gel electrophoresis. [i#ORL J Otorhinolaryngol Relat Spec#1i] 2004; [b#66#1b]: 233-40.
153. Hsueh PR, Teng LJ, Lee LN [i#et al.#1i] Increased prevalence of erythromycin resistance in streptococci: Substantial upsurge in erythromycin-resistant M phenotype in [i#Streptococcus pyogenes#1i] (1979-1998) but not in [i#Streptococcus pneumoniae#1i] (1985-1999) in Taiwan. [i#Microb Drug Resist#1i] 2002; [b#8#1b]: 27-33.
154. Farrell DJ, Morrissey I, Bakker S [i#et al.#1i] Molecular epidemiology of multiresistant [i#Streptococcus pneumoniae#1i] with both [i#erm(B)#1i]- and [i#mef#1i](A)-mediated macrolide resistance. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 764-8.
155. Brown SD, Farrell DJ, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of [i#Streptococcus pneumoniae#1i] collected during the 2000-2001 PROTEKT US Study. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 4980-7.
156. Jacobs MR, Johnson CE. Macrolide resistance: An increasing concern for treatment failure in children. [i#Pediatr Infect Dis J#1i] 2003; [b#22#1b] S131-8.
157. Fotopoulou N, Tassios PT, Beste DV [i#et al.#1i] A common clone of erythromycin-resistant [i#Streptococcus pneumoniae#1i] in Greece and the UK. [i#Clin Microbiol Infect#1i] 2003; [b#9#1b]: 924-9.
158. Monaco M, Camilli R, D'Ambrosio F [i#et al.#1i] Evolution of erythromycin resistance in [i#Streptococcus pneumoniae#1i] in Italy. [i#J Antimicrob Chemother#1i] 2005; [b#55#1b]: 256-9.
159. Wierzbowski AK, Swedlo D, Boyd D [i#et al.#1i] Molecular epidemiology and prevalence of macrolide efflux genes [i#mefA#1i] and [i#mefE#1i] in [i#Streptococcus pneumoniae#1i] obtained in Canada from 1997 to 2002. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1257-61.
160. Bonofiglio L, Ojeda MI, de Mier C [i#et al.#1i] Phenotypic and genotypic characterization of macrolide resistant [i#Streptococcus pneumoniae#1i] recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital. [i#Int J Antimicrob Agents#1i] 2005; [b#25#1b] 260-3.
161. Hotomi M, Billal DS, Shimada J [i#et al.#1i] Increase of macrolide-resistant [i#Streptococcus pneumoniae#1i] expressing [i#mefE#1i] or [i#ermB#1i] gene in the nasopharynx among children with otitis media. [i#Laryngoscope#1i] 2005; [b#115#1b]: 317-20.
162. Beekmann SE, Heilmann KP, Richter SS [i#et al.#1i] Antimicrobial
163. Ardanuy C, Tubau F, Linares J [i#et al.#1i] Distribution of subclasses [i#mefA#1i] and [i#mefE#1i] of the [i#mefA#1i] gene among clinical isolates of macrolide-resistant (M-phenotype) [i#Streptococcus pneumoniae#1i], viridans group streptococci, and [i#Streptococcus pyogenes. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 827-9.
164. Desjardins M, Delgaty KL, Ramotar K [i#et al.#1i] Prevalence and mechanisms of erythromycin resistance in group A and group B streptococcus: Implications for reporting susceptibility results. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 5620-3.
165. Ko WC, Yan JJ, Lee NY [i#et al.#1i] Polyclonal spread of erythromycin-resistant [i#Streptococcus agalactiae#1i] in southern Taiwan. [i#Microb Drug Resist#1i] 2004; [b#10#1b]: 306-12.
166. Cerda Zolezzi P, Laplana LM, Calvo CR [i#et al.#1i] Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and [i#Gemella#1i] spp. and transfer of resistance genes to [i#Streptococcus pneumoniae. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3462-7.
167. Bozdogan B, Appelbaum PC. Macrolide resistance in streptococci and [i#Haemophilus influenzae. Clin Lab Med#1i] 2004; [b#24#1b]: 455-75.
168. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: Molecular mechanisms and resistance phenotypes. [i#Clin Infect Dis#1i] 2004; [b#38#1b] Suppl 4: S322-7.
169. Cousin SL, Jr, Whittington WL, Roberts MC. Acquired macrolide resistance genes and the 1 bp deletion in the [i#mtrR#1i] promoter in [i#Neisseria gonorrhoeae. J Antimicrob Chemother#1i] 2003; [b#51#1b]: 131-3.
170. Wang Y, Wang GR, Shelby A [i#et al.#1i] A newly discovered [i#Bacteroides#1i] conjugative transposon, CTnGERM1, contains genes also found in gram-positive bacteria. [i#Appl Environ Microbiol#1i] 2003; [b#69#1b]: 4595-603.
171. Ojo KK, Ulep C, Van Kirk N [i#et al.#1i] The [i#mef#1i](A) gene predominates among seven macrolide resistance genes identified in gram-negative strains representing 13 genera, isolated from healthy Portuguese children. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3451-6.
172. Cousin S, Jr, Whittington WL, Roberts MC. Acquired macrolide resistance genes in pathogenic [i#Neisseria#1i] spp. isolated between 1940 and 1987. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 3877-80.
173. Lebel S, Bouttier S, Lambert T. The [i#cme#1i] gene of [i#Clostridium difficile#1i] confers multidrug resistance in [i#Enterococcus faecalis. FEMS Microbiol Lett#1i] 2004; [b#238#1b]: 93-100.
174. Reynolds E, Ross JI, Cove JH. Msr(A) and related macrolide/streptogramin resistance determinants: Incomplete transporters? [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 228-36.
175. Lina G, Quaglia A, Reverdy ME [i#et al.#1i] Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 1062-6.
176. Schmitz FJ, Sadurski R, Kray A [i#et al.#1i] Prevalence of macrolide-resistance genes in [i#Staphylococcus aureus#1i] and [i#Enterococcus faecium#1i] isolates from 24 European university hospitals. [i#J Antimicrob Chemother#1i] 2000; [b#45#1b]: 891-4.
177. Haroche J, Morvan A, Davi M [i#et al.#1i] Clonal diversity among streptogramin A-resistant [i#Staphylococcus aureus#1i] isolates collected in French hospitals. [i#J Clin Microbiol#1i] 2003; [b#41#1b]: 586-91.
178. Haroche J, Allignet J, Buchrieser C [i#et al.#1i] Characterization of a variant of [i#vga#1i](A) conferring resistance to streptogramin A and related compounds. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 2271-5.
179. Allignet J, El Solh N. Characterization of a new staphylococcal gene, [i#vgaB#1i], encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. [i#Gene#1i] 1997; [b#202#1b]: 133-8.
180. Haroche J, Allignet J, El Solh N. Tn[i#5406#1i], a new staphylococcal transposon conferring resistance to streptogramin a and related compounds including dalfopristin. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2337-43.
181. Portillo A, Ruiz-Larrea F, Zarazaga M [i#et al.#1i] Macrolide resistance genes in [i#Enterococcus#1i] spp. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 967-71.
182. Singh KV, Malathum K, Murray BE. Disruption of an [i#Enterococcus faecium#1i] species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b] 263-6.
183. Hayes JR, Wagner DD, English LL [i#et al.#1i] Distribution of streptogramin resistance determinants among [i#Enterococcus faecium#1i] from a poultry production environment of the USA. [i#J Antimicrob Chemother#1i] 2005; [b#55#1b]: 123-6.
184. Chesneau O, Ligeret H, Hosan-Aghaie N [i#et al.#1i] Molecular analysis of resistance to streptogramin a compounds conferred by the Vga proteins of staphylococci. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 973-80.
185. Banks DJ, Porcella SF, Barbian KD [i#et al.#1i] Structure and distribution of an unusual chimeric genetic element encoding macrolide resistance in phylogenetically diverse clones of group A [i#Streptococcus. J Infect Dis#1i] 2003; [b#188#1b]: 1898-908.
186. Singh KV, Weinstock GM, Murray BE. An [i#Enterococcus faecalis#1i] ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 1845-50.
187. Dina J, Malbruny B, Leclercq R. Nonsense mutations in the [i#Isa#1i]-like gene in [i#Enterococcus faecalis#1i] isolates susceptible to lincosamides and streptogramins A. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2307-9.
188. Kehrenberg C, Ojo KK, Schwarz S. Nucleotide sequence and organization of the multiresistance plasmid pSCFS1 from [i#Staphylococcus sciuri. J Antimicrob Chemother#1i] 2004; [b#54#1b]: 936-9.
189. Giovanetti E, Brenciani A, Burioni R [i#et al.#1i] A novel efflux system in inducibly erythromycin-resistant strains of [i#Streptococcus pyogenes. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3750-5.
190. Murata M, Ohno S, Kumano M [i#et al.#1i] Multidrug resistant phenotype of [i#Bacillus subtilis#1i] spontaneous mutants isolated in the presence of puromycin and lincomycin. [i#Can J Microbiol#1i] 2003; [b#49#1b]: 71-7.
191. Kumano M, Fujita M, Nakamura K [i#et al.#1i] Lincomycin resistance mutations in two regions immediately downstream of the -10 region of [i#lmr#1i] promoter cause overexpression of a putative multidrug efflux pump in [i#Bacillus subtilis#1i] mutants. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 432-5.
192. Kim HJ, Kim Y, Lee MS [i#et al.#1i] Gene [i#lmrB#1i] of [i#Corynebacterium glutamicum#1i] confers efflux-mediated resistance to lincomycin. [i#Mol Cells#1i] 2001; [b#12#1b]: 112-6.
193. Huang J, O'Toole PW, Shen W [i#et al.#1i] Novel chromosomally encoded multidrug efflux transporter MdeA in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 909-17.
194. Szczepanowski R, Krahn I, Linke B [i#et al.#1i] Antibiotic multiresistance plasmid pRSB101 isolated from a wastewater treatment plant is related to plasmids residing in phytopathogenic bacteria and carries eight different resistance determinants including a multidrug transport system. [i#Microbiology#1i] 2004; [b#150#1b]: 3613-30.
195. Poole K. Outer membranes and efflux: The path to multidrug resistance in gram-negative bacteria. [i#Curr Pharm Biotechnol#1i] 2002; [b#3#1b]: 77-98.
196. Chollet R, Chevalier J, Bryskier A [i#et al.#1i] The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in [i#Enterobacter aerogenes#1i] and [i#Escherichia coli. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3621-4.
197. Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in [i#Escherichia coli#1i] mutants selected with a fluoroquinolone. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 1467-72.
198. Zarantonelli L, Borthagaray G, Lee EH [i#et al.#1i] Decreased azithromycin susceptibility of [i#Neisseria gonorrhoeae#1i] due to [i#mtrR#1i] mutations. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2468-72.
199. Zarantonelli L, Borthagaray G, Lee EH [i#et al.#1i] Decreased susceptibility to azithromycin and erythromycin mediated by a novel [i#mtr(R)#1i] promoter mutation in [i#Neisseria gonorrhoeae. J Antimicrob Chemother#1i] 2001; [b#47#1b]: 651-4.
200. Peric M, Bozdogan B, Jacobs MR [i#et al.#1i] Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of [i#Haemophilus influenzae#1i] clinical isolates. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 1017-22.
201. Peric M, Bozdogan B, Galderisi C [i#et al.#1i] Inability of L22 ribosomal protein alteration to increase macrolide MICs in the absence of efflux mechanism in [i#Haemophilus influenzae#1i] HMC-S. [i#J Antimicrob Chemother#1i] 2004; [b#54#1b]: 393-400.
202. Tauch A, Schluter A, Bischoff N [i#et al.#1i] The 79, 370-bp conjugative plasmid pB4 consists of an IncP-1β backbone loaded with a chromate resistance transposon, the [i#strA-strB#1i] streptomycin resistance gene pair, the oxacillinase gene [i#bla#1i](NPS-1), and a tripartite antibiotic efflux system of the resistance-nodulation-division family. [i#Mol Genet Genomics#1i] 2003; [b#268#1b]: 570-84.
203. Mamelli L, Amoros JP, Pages JM [i#et al.#1i] A phenylalanine-arginine β-naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of [i#Campylobacter#1i] to macrolides. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 237-41.
204. Lin J, Michel LO, Zhang Q. Cme ABC functions as a multidrug efflux system in [i#Campylobacter jejuni. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2124-31.
205. Ball P. Quinolone generations: Natural history or natural selection? [i#J Antimicrob Chemother#1i] 2000; [b#46#1b] Suppl T1: 17-24.
206. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial infections. [i#Curr Pharm Des#1i] 2004; [b#10#1b]: 3213-20.
207. Fish DN. Levofloxacin: Update and perspectives on one of the original 'respiratory quinolones'. [i#Expert Rev Anti Infect Ther#1i] 2003; [b#1#1b] 371-87.
208. O'Donnell JA, Gelone SP. The newer fluoroquinolones. [i#Infect Dis Clin North Am#1i] 2004; [b#18#1b]: 691-716.
209. Schito AM, Schito GC. Levofloxacin, a broad spectrum anti-infective: from [i#Streptococcus pneumoniae#1i] to [i#Pseudomonas aeruginosa. J Chemother#1i] 2004; [b#16#1b] Suppl 2: 3-7.
210. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 2595-9.
211. Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 2233-41.
212. Schmitz FJ, Higgins PG, Mayer S [i#et al.#1i] Activity of quinolones against gram-positive cocci: Mechanisms of drug action and bacterial resistance. [i#Eur J Clin Microbiol Infect Dis#1i] 2002; [b#21#1b]: 647-59.
213. Kaatz GW, Moudgal VV, Seo SM. Identification and characterization of a novel efflux-related multidrug resistance phenotype in [i#Staphylococcus aureus. J Antimicrob Chemother#1i] 2002; [b#50#1b]: 833-8.
214. Brenwald NP, Appelbaum P, Davies T [i#et al.#1i] Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in [i#Streptococcus pneumoniae. Clin Microbiol Infect#1i] 2003; [b#9#1b]: 140-3.
215. Kaatz GW, Seo SM. Inducible NorA-mediated multidrug resistance in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 1995; [b#39#1b]: 2650-5.
216. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 1993; [b#37#1b] 1086-94.
217. Tanaka M, Wang T, Onodera Y [i#et al.#1i] Mechanism of quinolone resistance in [i#Staphylococcus aureus. J Infect Chemother#1i] 2000; [b#6#1b] 131-9.
218. Oizumi N, Kawabata S, Hirao M [i#et al.#1i] Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant [i#Staphylococcus aureus. J Infect Chemother#1i] 2001; [b#7#1b]: 191-4.
219. Kaatz GW, Seo SM, Foster TJ. Introduction of a [i#norA#1i] promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of [i#Staphylococcus aureus#1i] using plasmid integration. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2222-4.
220. Ng EYW, Truckis M, Hooper DC. Quinolone resistance mediated by [i#norA#1i] physiological characterization and relationship to [i#flgB#1i], a quinolone resistance locus on the [i#Staphylococcus aureus#1i] chromosome. [i#Antimicrob Agents Chemother#1i] 1994; [b#38#1b]: 1345-55.
221. Fournier B, Truong-Bolduc QC, Zhang X [i#et al.#1i] A mutation in the 5′ untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of [i#Staphylococcus aureus. J Bacteriol#1i] 2001; [b#183#1b]: 2367-71.
222. Piddock LJ, Jin YF, Webber MA [i#et al.#1i] Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2276-8.
223. Truong-Bolduc QC, Zhang X, Hooper DC. Characterization of NorR protein, a multifunctional regulator of [i#norA#1i] expression in [i#Staphylococcus aureus. J Bacteriol#1i] 2003; [b#185#1b]: 3127-38.
224. Roychoudhury S, Twinem TL, Makin KM [i#et al. Staphylococcus aureus#1i] mutants isolated via exposure to nonfluorinated quinolones: Detection of known and unique mutations. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 3422-6.
225. Daporta MT, Munoz Bellido JL, Guirao GY [i#et al. In vitro#1i] activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant [i#Streptococcus pneumoniae. Int J Antimicrob Agents#1i] 2004; [b#24#1b]: 185-7.
226. Mayer S, Boos M, Kohrer K [i#et al. In vitro#1i] development of resistance to newer fluoroquinolones in [i#Streptococcus pneumoniae#1i] isolates with reduced susceptibility to ciprofloxacin. [i#Eur J Clin Microbiol Infect Dis#1i] 2001; [b#20#1b]: 288-91.
227. Johnson AP, Sheppard CL, Harnett SJ [i#et al.#1i] Emergence of a fluoroquinolone-resistant strain of [i#Streptococcus pneumoniae#1i] in England. [i#J Antimicrob Chemother#1i] 2003; [b#52#1b]: 953-60.
228. Pletz MW, McGee L, Jorgensen J [i#et al.#1i] Levofloxacin-resistant invasive [i#Streptococcus pneumoniae#1i] in the United States: Evidence for clonal spread and the impact of conjugate pneumococcal vaccine. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3491-7.
229. De La Campa AG, Balsalobre L, Ardanuy C [i#et al.#1i] Fluoroquinolone resistance in penicillin-resistant [i#Streptococcus pneumoniae#1i] clones, Spain. [i#Emerg Infect Dis#1i] 2004; [b#10#1b]: 1751-9.
230. Azoulay-Dupuis E, Bedos JP, Mohler J [i#et al.#1i] Activity of gemifloxacin against quinolone-resistant [i#Streptococcus pneumoniae#1i] strains [i#in vitro#1i] and in a mouse pneumonia model. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1046-54.
231. Ferrandiz MJ, Oteo J, Aracil B [i#et al.#1i] Drug efflux and [i#parC#1i] mutations are involved in fluoroquinolone resistance in viridans group streptococci. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2520-3.
232. Guerin F, Varon E, Hoi AB [i#et al.#1i] Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 2197-200.
233. Beyer R, Pestova E, Millichap JJ [i#et al.#1i] A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by [i#Streptococcus pneumoniae#1i] and [i#Staphylococcus aureus#1i]: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 798-801.
234. Godreuil S, Galimand M, Gerbaud G [i#et al.#1i] Efflux pump Lde is associated with fluoroquinolone resistance in [i#Listeria monocytogenes. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 704-8.
235. Lynch C, Courvalin P, Nikaido H. Active efflux of antimicrobial agents in wild-type strains of Enterococci. [i#Antimicrob Agents Chemother#1i] 1997; [b#41#1b]: 869-71.
236. Jonas BM, Murray BE, Weinstock GM. Characterization of EmeA, a NorA homolog and multidrug resistance efflux pump, in [i#Enterococcus faecalis. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 3574-9.
237. Lee EW, Chen J, Huda MN [i#et al.#1i] Functional cloning and expression of [i#emeA#1i], and characterization of EmeA, a multidrug efflux pump from [i#Enterococcus faecalis. Biol Pharm Bull#1i] 2003; [b#26#1b]: 266-70.
238. Grohs P, Podglajen I, Gutmann L. Activities of different fluoroquinolones against [i#Bacillus anthracis#1i] mutants selected [i#in vitro#1i] and harboring topoisomerase mutations. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3024-7.
239. Bast DJ, Athamna A, Duncan CL [i#et al.#1i] Type II topoisomerase mutations in [i#Bacillus anthracis#1i] associated with high-level fluoroquinolone resistance. [i#J Antimicrob Chemother#1i] 2004; [b#54#1b]: 90-4.
240. Read TD, Salzberg SL, Pop M [i#et al.#1i] Comparative genome sequencing for discovery of novel polymorphisms in [i#Bacillus anthracis. Science#1i] 2002; [b#296#1b]: 2028-33.
241. Konings WN, Poelarends GJ. Bacterial multidrug resistance mediated by a homologue of the human multidrug transporter P-glycoprotein. [i#IUBMB Life#1i] 2002; [b#53#1b]: 213-8.
242. Raherison S, Gonzalez P, Renaudin H [i#et al.#1i] Increased expression of two multidrug transporter-like genes is associated with ethidium bromide and ciprofloxacin resistance in [i#Mycoplasma hominis. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 421-4.
243. Raherison S, Gonzalez P, Renaudin H [i#et al.#1i] Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by [i#Mycoplasma hominis. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 672-9.
244. Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in [i#Mycobacterium smegmatis. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 2415-23.
245. Pasca MR, Guglierame P, Arcesi F [i#et al.#1i] Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in [i#Mycobacterium tuberculosis. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3175-8.
246. Banerjee SK, Bhatt K, Rana S [i#et al.#1i] Involvement of an efflux system in mediating high level of fluoroquinolone resistance in [i#Mycobacterium smegmatis. Biochem Biophys Res Commun#1i] 1996; [b#226#1b]: 362-8.
247. Siddiqi N, Das R, Pathak N [i#et al. Mycobacterium tuberculosis#1i] isolate with a distinct genomic identity overexpresses a Tap-like efflux pump. [i#Infection#1i] 2004; [b#32#1b]: 109-11.
248. Rella M, Haas D. Resistance of [i#Pseudomonas aeruginosa#1i] PAO to nalidixic acid and low levels of β-lactam antibiotics: Mapping of chromosomal genes. [i#Antimicrob Agents Chemother#1i] 1982; [b#22#1b]: 242-9.
249. Hirai K, Suzue S, Irikura T [i#et al.#1i] Mutations producing resistance to norfloxacin in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 1987; [b#31#1b]: 582-6.
250. Celesk RA, Robillard RA. Factors influencing the accumulation of ciprofloxacin in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 1989; [b#33#1b]: 1921-6.
251. Chamberland S, Bayer AS, Schollaardt T [i#et al.#1i] Characterization of mechanisms of quinolone resistance in [i#Pseudomonas aeruginosa#1i] strains isolated [i#in vitro#1i] and [i#in vivo#1i] during experimental endocarditis. [i#Antimicrob Agents Chemother#1i] 1989; [b#33#1b]: 624-34.
252. Poole K. Efflux pumps. In Ramos J-L, ed. [i#Pseudomonas, Vol. I. Genomics, Life Style and Molecular Architecture#1i]. New York: Kluwer Academic/Plenum Publishers, 2004; 635-74.
253. Poole K. Multidrug efflux pumps and antimicrobial resistance in [i#Pseudomonas aeruginosa#1i] and related organisms. In Paulsen IT, Lewis K, eds. [i#Microbial Multidrug Efflux#1i]. UK: Horizon Scientific Press, 2003; 273-98.
254. Poole K, Srikumar R. Multidrug efflux in [i#Pseudomonas aeruginosa#1i]: components, mechanisms and clinical significance. [i#Curr Top Med Chem#1i] 2001; [b#1#1b]: 59-71.
255. Dupont P, Hocquet D, Jeannot K [i#et al.#1i] Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of [i#Pseudomonas aeruginosa. J Antimicrob Chemother#1i] 2005; [b#55#1b]: 518-22.
256. Kriengkauykiat J, Porter E, Lomovskaya O [i#et al.#1i] Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 565-70.
257. Giraud E, Blanc G, Bouju-Albert A [i#et al.#1i] Mechanisms of quinolone resistance and clonal relationship among [i#Aeromonas salmonicida#1i] strains isolated from reared fish with furunculosis. [i#J Med Microbiol#1i] 2004; [b#53#1b]: 895-901.
258. Pumbwe L, Randall LP, Woodward MJ [i#et al.#1i] Expression of the efflux pump genes [i#cmeB, cmeF#1i] and the porin gene [i#porA#1i] in multiple-antibiotic-resistant [i#Campylobacter jejuni. J Antimicrob Chemother#1i] 2004; [b#54#1b]: 341-7.
259. Zhang Q, Lin J, Pereira S. Fluoroquinolone-resistant [i#Campylobacter#1i] in animal reservoirs: Dynamics of development, resistance mechanisms and ecological fitness. [i#Anim Health Res Rev#1i] 2003; [b#4#1b]: 63-71.
260. Linde HJ, Notka F, Irtenkauf C [i#et al.#1i] Increase in MICs of ciprofloxacin [i#in vivo#1i] in two closely related clinical isolates of [i#Enterobacter cloacae. J Antimicrob Chemother#1i] 2002; [b#49#1b]: 625-30.
261. Mazzariol A, Tokue Y, Kanegawa TM [i#et al.#1i] High-level fluoroquinolone-resistant clinical isolates of [i#Escherichia coli#1i] overproduce multidrug efflux protein AcrA. [i#Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 3441-3.
262. Wang H, Dzink-Fox JL, Chen M [i#et al.#1i] Genetic characterization of highly fluoroquinolone-resistant clinical [i#Escherichia coli#1i] strains from China: Role of [i#acrR#1i] mutations. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 1515-21.
263. Gruteke P, Goessens W, Van Gils J [i#et al.#1i] Patterns of resistance associated with integrons, the extended-spectrum β-lactamase SHV-5 gene, and a multidrug efflux pump of [i#Klebsiella pneumoniae#1i] causing a nosocomial outbreak. [i#J Clin Microbiol#1i] 2003; [b#41#1b]: 1161-6.
264. Wagenlehner FM, Heisig P, Irtenkauf C [i#et al.#1i] Clinically significant borderline resistance of sequential clinical isolates of [i#Klebsiella pneumoniae. Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 367-73.
265. Mazzariol A, Zuliani J, Cornaglia G [i#et al.#1i] AcrAB efflux system: expression and contribution to fluoroquinolone resistance in [i#Klebsiella#1i] spp. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3984-6.
266. del Mar TM, Vila J, Ruiz J [i#et al.#1i] Decreased permeability and enhanced proton-dependent active efflux in the development of resistance to quinolones in [i#Morganella morganii. Int J Antimicrob Agents#1i] 2000; [b#14#1b]: 157-60.
267. Oh H, Stenhoff J, Jalal S [i#et al.#1i] Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant [i#Pseudomonas aeruginosa#1i] strains. [i#Microb Drug Resist#1i] 2003; [b#9#1b]: 323-8.
268. Teresa TM, Martin JL, Navia M [i#et al.#1i] Mechanisms of fluoroquinolone resistance in [i#Pseudomonas aeruginosa#1i] isolates from canine infections. [i#Vet Microbiol#1i] 2003; [b#94#1b]: 295-301.
269. Higgins PG, Fluit AC, Milatovic D [i#et al.#1i] Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of [i#Pseudomonas aeruginosa. Int J Antimicrob Agents#1i] 2003; [b#21#1b]: 409-13.
270. Le Thomas I, Couetdic G, Clermont O [i#et al. In vivo#1i] selection of a target/efflux double mutant of [i#Pseudomonas aeruginosa#1i] by ciprofloxacin therapy. [i#J Antimicrob Chemother#1i] 2001; [b#48#1b]: 553-5.
271. Llanes C, Hocquet D, Vogne C [i#et al.#1i] Clinical strains of [i#Pseudomonas aeruginosa#1i] overproducing MexAB-OprM and MexXY efflux pumps simultaneously. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1797-802.
272. Escribano I, Rodriguez JC, Cebrian L [i#et al.#1i] The importance of active efflux systems in the quinolone resistance of clinical isolates of [i#Salmonella#1i] spp. [i#Int J Antimicrob Agents#1i] 2004; [b#24#1b]: 428-32.
273. Olliver A, Valle M, Chaslus-Dancla E [i#et al.#1i] Role of an [i#acrR#1i] mutation in multidrug resistance of [i#in vitro#1i]-selected fluoroquinolone-resistant mutants of [i#Salmonella enterica#1i] serovar Typhimurium. [i#FEMS Microbiol Lett#1i] 2004; [b#238#1b]: 267-72.
274. Baucheron S, Chaslus-Dancla E, Cloeckaert A. Role of [i#tolC#1i] and [i#parC#1i] mutation in high-level fluoroquinolone resistance in [i#Salmonella enterica#1i] serotype Typhimurium DT204. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 657-9.
275. Casin I, Breuil J, Darchis JP [i#et al.#1i] Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in [i#Salmonella enterica#1i] typhimurium isolates in humans. [i#Emerg Infect Dis#1i] 2003; [b#9#1b]: 1455-7.
276. Soto SM, Ruiz J, Mendoza MC [i#et al. In vitro#1i] fluoroquinolone-resistant mutants of [i#Salmonella enterica#1i] serotype Enteritidis: Analysis of mechanisms involved in resistance. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 537-40.
277. Cebrian L, Rodriguez JC, Escribano I [i#et al.#1i] Characterization of [i#Salmonella#1i] spp. mutants with reduced fluoroquinolone susceptibility: importance of efflux pump mechanisms. [i#Chemotherapy (Basel)#1i] 2005; [b#51#1b]: 40-3.
278. Kumar A, Worobec EA. Fluoroquinolone resistance of [i#Serratia marcescens#1i]: Involvement of a proton gradient-dependent efflux pump. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 593-6.
279. Kumar A, Worobec EA. Cloning, sequencing, and characterization of the SdeAB multidrug efflux pump of [i#Serratia marcescens. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1495-501.
280. Chang LL, Chen HF, Chang CY [i#et al.#1i] Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of [i#Stenotrophomonas maltophilia. J Antimicrob Chemother#1i] 2004; [b#53#1b]: 518-21.
281. Ricci V, Peterson ML, Rotschafer JC [i#et al.#1i] Role of topoisomerase mutations and efflux in fluoroquinolone resistance of [i#Bacteroides fragilis#1i] clinical isolates and laboratory mutants. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1344-6.
282. Ricci V, Piddock L. Accumulation of garenoxacin by [i#Bacteroides fragilis#1i] compared with that of five fluoroquinolones. [i#J Antimicrob Chemother#1i] 2003; [b#52#1b]: 605-9.
283. Dewi BE, Akira S, Hayashi H [i#et al.#1i] High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant [i#Neisseria gonorrhoeae. Sex Transm Dis#1i] 2004; [b#31#1b]: 353-9.
284. Capilla S, Ruiz J, Goni P [i#et al.#1i] Characterization of the molecular mechanisms of quinolone resistance in [i#Yersinia enterocolitica#1i] O:3 clinical isolates. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 1068-71.
285. Ribera A, Ruiz J, Jiminez de Anta MT [i#et al.#1i] Effect of an efflux pump inhibitor on the MIC of nalidixic acid for [i#Acinetobacter baumannii#1i] and [i#Stenotrophomonas maltophilia#1i] clinical isolates. [i#J Antimicrob Chemother#1i] 2002; [b#49#1b]: 697-8.
286. Higgins PG, Wisplinghoff H, Stefanik D [i#et al.#1i] Selection of topoisomerase mutations and overexpression of [i#adeB#1i] mRNA transcripts during an outbreak of [i#Acinetobacter baumannii. J Antimicrob Chemother#1i] 2004; [b#54#1b]: 821-3.
287. Kern WV, Oethinger M, Jellen-Ritter AS [i#et al.#1i] Non-target gene mutations in the development of fluoroquinolone resistance in [i#Escherichia coli. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 814-20.
288. Alekshun MN, Levy SB. The [i#mar#1i] regulon: Multiple resistance to antibiotics and other toxic chemicals. [i#Trends Microbiol#1i] 1999; [b#7#1b] 410-3.
289. Maneewannakul K, Levy SB. Identification for [i#mar#1i] mutants among quinolone-resistant clinical isolates of [i#Escherichia coli. Antimicrob Agents Chemother#1i] 1996; [b#40#1b]: 1695-8.
290. Golding SS, Matthews KR. Intrinsic mechanism decreases susceptibility of [i#Escherichia coli#1i] O157:H7 to multiple antibiotics. [i#J Food Prot#1i] 2004; [b#67#1b]: 34-9.
291. Yaron S, White DG, Matthews KR. Characterization of an [i#Escherichia coli#1i] O157:H7 [i#marR#1i] mutant. [i#Int J Food Microbiol#1i] 2003; [b#85#1b]: 281-91.
292. Ba BB, Feghali H, Arpin C [i#et al.#1i] Activities of ciprofloxacin and moxifloxacin against [i#Stenotrophomonas maltophilia#1i] and emergence of resistant mutants in an [i#in vitro#1i] pharmacokinetic-pharmacodynamic model. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 946-53.
293. Huda N, Lee EW, Chen J [i#et al.#1i] Molecular cloning and characterization of an ABC multidrug efflux pump, VcaM, in Non-O1 [i#Vibrio cholerae. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2413-7.
294. Yang S, Clayton SR, Zechiedrich EL. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in [i#Escherichia coli. J Antimicrob Chemother#1i] 2003; [b#51#1b]: 545-56.
295. Chan YY, Tan TM, Ong YM [i#et al.#1i] BpeAB-OprB, a multidrug efflux pump in [i#Burkholderia pseudomallei. Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1128-35.
296. Li X-Z, Poole K, Nikaido H. Contributions of MexAB-OprM and an EmrE homologue to intrinsic resistance of [i#Pseudomonas aeruginosa to aminoglycosides and dyes. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b] 27-33.
297. Miller GH, Sabatelli FJ, Naples L [i#et al.#1i] Resistance to aminoglycosides in [i#Pseudomonas#1i]. Aminoglycoside Resistance Study Groups. [i#Trends Microbiol#1i] 1994; [b#2#1b]: 347-53.
298. Miller GH, Sabatelli FJ, Naples L [i#et al.#1i] The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. [i#J Chemother#1i] 1995; [b#7#1b] Suppl 2: 31-44.
299. Miller GH, Sabatelli FJ, Naples L [i#et al.#1i] The most frequently occurring aminoglycoside resistance mechanisms - combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. [i#J Chemother#1i] 1995; [b#7#1b] Suppl 2: 17-30.
300. Price KE, Kresel PA, Farchione LA [i#et al.#1i] Epidemiological studies of aminoglycoside resistance in the U.S.A. [i#J Antimicrob Chemother#1i] 1981; [b#8#1b] Suppl A: 89-105.
301. Phillips I, King A, Shannon K. Prevalence and mechanisms of aminoglycoside resistance. A ten-year study. [i#Am J Med#1i] 1986; [b#80#1b] 48-55.
302. Shimizu K, Kumada T, Hsieh WC [i#et al.#1i] Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. [i#Antimicrob Agents Chemother#1i] 1985; [b#28#1b]: 282-8.
303. MacLeod DL, Nelson LE, Shawar RM [i#et al.#1i] Aminoglycoside-resistance mechanisms for cystic fibrosis [i#Pseudomonas aeruginosa#1i] isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. [i#J Infect Dis#1i] 2000; [b#181#1b]: 1180-4.
304. Hurley JC, Miller GH, Smith AL. Mechanism of amikacin resistance in [i#Pseudomonas aeruginosa#1i] isolates from patients with cystic fibrosis. [i#Diagn Microbiol Infect Dis#1i] 1995; [b#22#1b]: 331-6.
305. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. [i#Chest#1i] 2001; [b#120#1b]: 118S-123S.
306. Saiman L, Mehar F, Niu WW [i#et al.#1i] Antibiotic susceptibility of multiply resistant [i#Pseudomonas aeruginosa#1i] isolated from patients with cystic fibrosis, including candidates for transplantation. [i#Clin Infect Dis#1i] 1996; [b#23#1b]: 532-7.
307. Shawar RM, MacLeod DL, Garber RL [i#et al.#1i] Activities of tobramycin and six other antibiotics against [i#Pseudomonas aeruginosa#1i] isolates from patients with cystic fibrosis. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2877-80.
308. Kettner M, Milosovic P, Hletkova M [i#et al.#1i] Incidence and mechanisms of aminoglycoside resistance in [i#Pseudomonas aeruginosa#1i] serotype O11 isolates. [i#Infection#1i] 1995; [b#23#1b]: 380-3.
309. Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in [i#Pseudomonas aeruginosa#1i] clinical isolates. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 3202-7.
310. Vogne C, Aires JR, Bailly C [i#et al.#1i] Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among [i#Pseudomonas aeruginosa#1i] isolates from patients with cystic fibrosis. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1676-80.
311. Westbrock-Wadman S, Sherman DR, Hickey MJ [i#et al.#1i] Characterization of a [i#Pseudomonas aeruginosa#1i] efflux pump contributing to aminoglycoside impermeability. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 2975-83.
312. Deplano A, Denis O, Poirel L [i#et al.#1i] Molecular characterization of an epidemic clone of panantibiotic-resistant [i#Pseudomonas aeruginosa. J Clin Microbiol#1i] 2005; [b#43#1b]: 1198-204.
313. Poole K. Aminoglycoside resistance in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 479-87.
314. Hocquet D, Vogne C, El Garch F [i#et al.#1i] MexXY-OprM efflux pump is necessary for adaptive resistance of [i#Pseudomonas aeruginosa#1i] to aminoglycosides. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 1371-5.
315. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. [i#Pharmacotherapy#1i] 1997; [b#17#1b]: 549-55.
316. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of [i#Pseudomonas aeruginosa#1i] by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: Substrate specificities of the efflux systems. [i#J Infect Chemother#1i] 2002; [b#8#1b] 371-3.
317. Okamoto K, Gotoh N, Nishino T. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2002; [b#46#1b] 2696-9.
318. Mazzariol A, Cornaglia G, Nikaido H. Contributions of the AmpC β-lactamase and the AcrAB multidrug efflux system in intrinsic
319. Masuda N, Gotoh N, Ishii C [i#et al.#1i] Interplay between chromosomal β-lactamase and the MexAB-OprM efflux system in intrinsic resistance to β-lactams in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 400-2.
320. Masuda N, Sakagawa E, Ohya S [i#et al.#1i] Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 3322-7.
321. Nikaido H, Basina M, Nguyen V [i#et al.#1i] Multidrug efflux pump AcrAB of [i#Salmonella typhimurium#1i] excretes only those β-lactam antibiotics containing lipophilic side chains. [i#J Bacteriol#1i] 1998; [b#180#1b]: 4686-92.
322. Nishino K, Yamada J, Hirakawa H [i#et al.#1i] Roles of TolC-dependent multidrug transporters of [i#Escherichia coli#1i] in resistance to β-lactams. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 3030-3.
323. Hirakawa H, Nishino K, Yamada J [i#et al.#1i] β-lactam resistance modulated by the overexpression of response regulators of two-component signal transduction systems in [i#Escherichia coli. J Antimicrob Chemother#1i] 2003; [b#52#1b]: 576-82.
324. Poole K. Resistance to β-lactam antibiotics. [i#Cell Mol Life Sci#1i] 2004; [b#61#1b]: 2200-23.
325. Pai H, Kim J, Kim J [i#et al.#1i] Carbapenem resistance mechanisms in [i#Pseudomonas aeruginosa#1i] clinical isolates. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 480-4.
326. Boutoille D, Corvec S, Caroff N [i#et al.#1i] Detection of an IS[i#21#1i] insertion sequence in the [i#mexR#1i] gene of [i#Pseudomonas aeruginosa#1i] increasing β-lactam resistance. [i#FEMS Microbiol Lett#1i] 2004; [b#230#1b]: 143-6.
327. Cavallo JD, Plesiat P, Couetdic G [i#et al.#1i] Mechanisms of β-lactam resistance in [i#Pseudomonas aeruginosa#1i]: Prevalence of OprM-overproducing strains in a French multicentre study (1997). [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 1039-43.
328. Poole K. Multidrug efflux pumps and antimicrobial resistance in [i#Pseudomonas aeruginosa#1i] and related organisms. [i#J Mol Microbiol Biotechnol#1i] 2001; [b#3#1b]: 255-64.
329. Köhler T, Epp SF, Curty LK [i#et al.#1i] Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of [i#Pseudomonas aeruginosa. J Bacteriol#1i] 1999; [b#181#1b]: 6300-5.
330. Ochs MM, McCusker MP, Bains M [i#et al.#1i] Negative regulation of the [i#Pseudomonas aeruginosa#1i] outer membrane porin OprD selective for imipenem and basic amino acids. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 1085-90.
331. Wolter DJ, Hanson ND, Lister PD. Insertional inactivation of [i#oprD#1i] in clinical isolates of [i#Pseudomonas aeruginosa#1i] leading to carbapenem resistance. [i#FEMS Microbiol Lett#1i] 2004; [b#236#1b]: 137-43.
332. Livermore DM. Of [i#Pseudomonas#1i], porins, pumps and carbapenems. [i#J Antimicrob Chemother#1i] 2001; [b#47#1b]: 247-50.
333. Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an [i#mtrR#1i] mutation is required for chromosomally mediated penicillin resistance in [i#Neisseria gonorrhoeae. J Bacteriol#1i] 2002; [b#184#1b]: 5619-24.
334. Kaczmarek FS, Gootz TD, Dib-Hajj F [i#et al.#1i] Genetic and molecular characterization of β-lactamase-negative ampicillin-resistant [i#Haemophilus influenzae#1i] with unusually high resistance to ampicillin. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1630-9.
335. Kallman O, Fendukly F, Karlsson I [i#et al.#1i] Contribution of efflux to cefuroxime resistance in clinical isolates of [i#Escherichia coli. Scand J Infect Dis#1i] 2003; [b#35#1b]: 464-70.
336. Fujisaki S, Ohnuma S, Horiuchi T [i#et al.#1i] Cloning of a gene from [i#Escherichia coli#1i] that confers resistance to fosmidomycin as a consequence of amplification. [i#Gene#1i] 1996; [b#175#1b]: 83-7.
337. Turnidge J, Collignon P. Resistance to fusidic acid. [i#Int J Antimicrob Agents#1i] 1999; [b#12#1b] Suppl 2: S35-S44.
338. Ramos J L, Duque E, Gallegos MT [i#et al.#1i] Mechanisms of solvent tolerance in gram-negative bacteria. [i#Annu Rev Microbiol#1i] 2002; [b#56#1b]: 743-68.
339. Fernandes P, Ferreira BS, Cabral JM. Solvent tolerance in bacteria: Role of efflux pumps and cross-resistance with antibiotics. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 211-6.
340. Randall LP, Cooles SW, Sayers AR [i#et al.#1i] Association between cyclohexane resistance in [i#Salmonella#1i] of different serovars and increased resistance to multiple antibiotics, disinfectants and dyes. [i#J Med Microbiol#1i] 2001; [b#50#1b]: 919-24.
341. Zhao S, Maurer JJ, Hubert S [i#et al.#1i] Antimicrobial susceptibility and molecular characterization of avian pathogenic [i#Escherichia coli#1i] isolates. [i#Vet Microbiol#1i] 2005; [b#107#1b]: 215-24.
342. Jude F, Arpin C, Brachet-Castang C [i#et al.#1i] TbtABM, a multidrug efflux pump associated with tributyltin resistance in [i#Pseudomonas stutzeri. FEMS Microbiol Lett#1i] 2004; [b#232#1b]: 7-14.
343. Nies DH. Efflux-mediated heavy metal resistance in prokaryotes. [i#FEMS Microbiol Rev#1i] 2003; [b#27#1b]: 313-39.
344. Poole K. Acquired resistance. In Fraise AP, Lambert PA, Maillard J-Y, eds. [i#Russell, Hugo & Ayliffe's Principles and Practice of Disinfection, Preservation & Sterilization#1i]. Oxford: Blackwell Publishing, 2004; 170-83.
345. Leelaporn A, Paulsen IT, Tennent JM [i#et al.#1i] Multidrug resistance to antiseptics and disinfectants in coagulase-negative staphylococci. [i#J Med Microbiol#1i] 1994; [b#40#1b]: 214-20.
346. Noguchi N, Hase M, Kitta M [i#et al.#1i] Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant [i#Staphylococcus aureus. FEMS Microbiol Lett#1i] 1999; [b#172#1b]: 247-53.
347. Kazama H, Hamashima H, Sasatsu M [i#et al.#1i] Distribution of the antiseptic-resistance gene [i#qacEΔ1#1i] in gram-positive bacteria. [i#FEMS Microbiol Lett#1i] 1998; [b#165#1b]: 295-9.
348. Bjorland J, Steinum T, Sunde M [i#et al.#1i] Novel plasmid-borne gene [i#qacJ#1i] mediates resistance to quaternary ammonium compounds in equine [i#Staphylococcus aureus, Staphylococcus simulans#1i], and [i#Staphylococcus intermedius. Antimicrob Agents Chemother#1i] 2003; [b#47#1b] 3046-52.
349. Bjorland J, Sunde M, Waage S. Plasmid-borne [i#smr#1i] gene causes resistance to quaternary ammonium compounds in bovine [i#Staphylococcus aureus. J Clin Microbiol#1i] 2001; [b#39#1b]: 3999-4004.
350. Heir E, Sundheim G, Holck AL. Identification and characterization of quaternary ammonium compound resistant staphylococci from the food industry. [i#Int J Food Microbiol#1i] 1999; [b#48#1b]: 211-9.
351. Sidhu MS, Heir E, Sorum H [i#et al.#1i] Genetic linkage between resistance to quaternary ammonium compounds and β-lactam antibiotics in food-related [i#Staphylococcus#1i] spp. [i#Microb Drug Resist#1i] 2001; [b#7#1b]: 363-71.
352. Heir E, Sundheim G, Holck AL. Resistance to quaternary ammonium compounds in [i#Staphylococcus#1i] spp. isolated from the food industry and nucleotide sequence of the resistance plasmid pST827. [i#J Appl Bacteriol#1i] 1995; [b#79#1b]: 149-56.
353. Noguchi N, Tamura M, Narui K [i#et al.#1i] Frequency and genetic characterization of multidrug-resistant mutants of [i#Staphylococcus aureus#1i] after selection with individual antiseptics and fluoroquinolones. [i#Biol Pharm Bull#1i] 2002; [b#25#1b]: 1129-32.
354. Noguchi N, Okada H, Narui K [i#et al.#1i] Comparison of the nucleotide sequence and expression of [i#norA#1i] genes and microbial susceptibility in 21 strains of [i#Staphylococcus aureus. Microb Drug Resist#1i] 2004; [b#10#1b]: 197-203.
355. Kaatz GW, McAleese F, Seo SM. Multidrug resistance in [i#Staphylococcus aureus#1i] due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b] 1857-64.
356. Lee EW, Huda MN, Kuroda T [i#et al.#1i] EfrAB, an ABC multidrug efflux pump in [i#Enterococcus faecalis. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 3733-8.
357. Kaatz GW, Seo SM, O'Brien L [i#et al.#1i] Evidence for the existence of a multidrug efflux transporter distinct from NorA in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 2000; [b#44#1b]: 1404-6.
358. Aase B, Sundheim G, Langsrud S [i#et al.#1i] Occurrence of and a possible mechanism for resistance to a quaternary ammonium compound in [i#Listeria monocytogenes. Int J Food Microbiol#1i] 2000; [b#62#1b]: 57-63.
359. To MS, Favrin S, Romanova N [i#et al.#1i] Postadaptational resistance to benzalkonium chloride and subsequent physicochemical modifications of [i#Listeria monocytogenes. Appl Environ Microbiol#1i] 2002; [b#68#1b]: 5258-64.
360. Silver S. Bacterial silver resistance: Molecular biology and uses and misuses of silver compounds. [i#FEMS Microbiol Rev#1i] 2003; [b#27#1b]: 341-53.
361. Barbolla R, Catalano M, Orman BE [i#et al.#1i] Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated [i#Stenotrophomonas maltophilia#1i] isolates. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 666-9.
362. Saenz Y, Brinas L, Dominguez E [i#et al.#1i] Mechanisms of resistance in multiple-antibiotic-resistant [i#Escherichia coli#1i] strains of human, animal, and food origins. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b] 3996-4001.
363. O'Halloran F, Lucey B, Cryan B [i#et al.#1i] Molecular characterization of class 1 integrons from Irish thermophilic [i#Campylobacter#1i] spp. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 952-7.
364. Kucken D, Feucht H, Kaulfers P. Association of [i#qacE#1i] and [i#qacEΔ1#1i] with multiple resistance to antibiotics and antiseptics in clinical isolates of Gram-negative bacteria. [i#FEMS Microbiol Lett#1i] 2000; [b#183#1b]: 95-8.
365. Morita Y, Murata T, Mima T [i#et al.#1i] Induction of [i#mexCD-oprJ#1i] operon for a multidrug efflux pump by disinfectants in wild-type [i#Pseudomonas aeruginosa#1i] PAO1. [i#J Antimicrob Chemother#1i] 2003; [b#5#1b] 991-4.
366. Langsrud S, Sundheim G, Holck AL. Cross-resistance to antibiotics of [i#Escherichia coli#1i] adapted to benzalkonium chloride or exposed to stress-inducers. [i#J Appl Microbiol#1i] 2004; [b#96#1b]: 201-8.
367. Braoudaki M, Hilton AC. Adaptive resistance to biocides in [i#Salmonella enterica#1i] and [i#Escherichia coli#1i] O157 and cross-resistance to antimicrobial agents. [i#J Clin Microbiol#1i] 2004; [b#42#1b]: 73-8.
368. Braoudaki M, Hilton AC. Mechanisms of resistance in [i#Salmonella enterica#1i] adapted to erythromycin, benzalkonium chloride and triclosan. [i#Int J Antimicrob Agents#1i] 2005; [b#25#1b]: 31-7.
369. + and is soluble in organic solvents. [i#J Biol Chem#1i] 1995; [b#270#1b]: 6856-63.
370. Nishino K, Yamaguchi A. Analysis of a complete library of putative drug transporter genes in [i#Escherichia coli. J Bacteriol#1i] 2001; [b#183#1b] 5803-12.
371. Nagai K, Murata T, Ohta S [i#et al.#1i] Two different mechanisms are involved in the extremely high-level benzalkonium chloride resistance of a [i#Pseudomonas fluorescens#1i] strain. [i#Microbiol Immunol#1i] 2003; [b#47#1b]: 709-15.
372. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. [i#Clin Microbiol Rev#1i] 2004; [b#17#1b]: 863-93, table.
373. Fang C-T, Chen H-C, Chuang Y-P [i#et al.#1i] Cloning of a cation efflux pump gene associated with chlorhexidine resistance in [i#Klebsiella pneumoniae. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2024-8.
374. Braoudaki M, Hilton AC. Low level of cross-resistance between triclosan and antibiotics in [i#Escherichia coli#1i] K-12 and [i#E. coli#1i] O55 compared to [i#E. coli#1i] O157. [i#FEMS Microbiol Lett#1i] 2004; [b#235#1b] 305-9.
375. Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. High-level triclosan resistance in [i#Pseudomonas aeruginosa#1i] is solely a result of efflux. [i#Am J Infect Control#1i] 2003; [b#31#1b]: 124-7.
376. Chen J, Kuroda T, Huda MN [i#et al.#1i] An RND-type multidrug efflux pump SdeXY from [i#Serratia marcescens. J Antimicrob Chemother#1i] 2003; [b#52#1b] 176-9.
377. Sanchez P, Moreno E, Martinez JL. The biocide triclosan selects [i#Stenotrophomonas maltophilia#1i] mutants that overproduce the SmeDEF multidrug efflux pump. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 781-2.
378. McMurry LM, Oethinger M, Levy SB. Overexpression of [i#marA, soxS,#1i] or [i#acrAB#1i] produces resistance to triclosan in laboratory and clinical strains of [i#Escherichia coli. FEMS Microbiol Lett#1i] 1998; [b#166#1b]: 305-9.
379. Pumbwe L, Randall LP, Woodward MJ [i#et al.#1i] Evidence for multiple-antibiotic resistance in [i#Campylobacter jejuni#1i] not mediated by CmeB or CmeF. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b] 1289-93.
380. Randall LP, Cooles SW, Piddock LJ [i#et al.#1i] Effect of triclosan or a phenolic farm disinfectant on the selection of antibiotic-resistant [i#Salmonella enterica. J Antimicrob Chemother#1i] 2004; [b#54#1b]: 621-7.
381. Randall LP, Ridley AM, Cooles SW [i#et al.#1i] Prevalence of multiple antibiotic resistance in 443 [i#Campylobacter#1i] spp. isolated from humans and animals. [i#J Antimicrob Chemother#1i] 2003; [b#52#1b]: 507-10.
382. Ikeda T, Yoshimura F. A resistance-nodulation-cell division family xenobiotic efflux pump in an obligate anaerobe, [i#Porphyromonas gingivalis. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3257-60.
383. Betts JC, McLaren A, Lennon MG [i#et al.#1i] Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated [i#Mycobacterium tuberculosis. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2903-13.
384. Gupta A, Phung LT, Taylor DE [i#et al.#1i] Diversity of silver resistance genes in IncH incompatibility group plasmids. [i#Microbiology#1i] 2001; [b#147#1b]: 3393-402.
385. Gilmour MW, Thomson NR, Sanders M [i#et al.#1i] The complete nucleotide sequence of the resistance plasmid R478: Defining the backbone components of incompatibility group H conjugative plasmids through comparative genomics. [i#Plasmid#1i] 2004; [b#52#1b]: 182-202.
386. Chen YT, Chang HY, Lai YC [i#et al.#1i] Sequencing and analysis of the large virulence plasmid pLVPK of [i#Klebsiella pneumoniae#1i] CG43. [i#Gene#1i] 2004; [b#337#1b]: 189-98.
387. Moken MC, McMurry LM, Levy SB. Selection of multiple-antibiotic-resistant (mar) mutants of [i#Escherichia coli#1i] by using the disinfectant pine oil: Roles of the [i#mar#1i] and [i#acrAB#1i] loci. [i#Antimicrob Agents Chemother#1i] 1997; [b#41#1b]: 2770-2.
388. Gilbert P, McBain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. [i#Clin Microbiol Rev#1i] 2003; [b#16#1b]: 189-208.
389. Fraise AP. Reply. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 139-40.
390. Fraise AP. Biocide abuse and antimicrobial resistance - a cause for concern? [i#J Antimicrob Chemother#1i] 2002; [b#49#1b]: 11-2.
391. Gilbert P, McBain AJ. Biocide usage in the domestic setting and concern about antibacterial and antibiotic resistance. [i#J Infect#1i] 2001; [b#43#1b]: 85-91.
392. Gilbert P, McBain AJ, Bloomfield SF. Biocide abuse and antimicrobial resistance: Being clear about the issues. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 137-9.
393. McBain AJ, Rickard AH, Gilbert P. Possible implications of biocide accumulation in the environment on the prevalence of bacterial antibiotic resistance. [i#J Ind Microbiol Biotechnol#1i] 2002; [b#29#1b]: 326-30.
394. Levy SB. Active efflux, a common mechanism for biocide and antibiotic resistance. [i#J Appl Microbiol#1i] 2002; [b#92#1b] Suppl: 65S-71S.
395. Chuanchuen R, Beinlich K, Hoang TT [i#et al.#1i] Cross-resistance between triclosan and antibiotics in [i#Pseudomonas aeruginosa#1i] is mediated by multidrug efflux pumps: Exposure of a susceptible mutant strain to triclosan selects [i#nfxB#1i] mutants overexpressing MexCD-OprJ. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 428-32.
396. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of [i#Pseudomonas aeruginosa#1i] requires OprM for antibiotic efflux but not for efflux of triclosan. [i#J Bacteriol#1i] 2002; [b#184#1b]: 5036-44.
397. Cole EC, Addison RM, Rubino JR [i#et al.#1i] Investigation of antibiotic and antibacterial agent cross-resistance in target bacteria from homes of antibacterial product users and nonusers. [i#J Appl Microbiol#1i] 2003; [b#95#1b]: 664-76.
398. Mosher RH, Camp DJ, Yang K [i#et al.#1i] Inactivation of chloramphenicol by O-phosphorylation. A novel resistance mechanism in [i#Streptomyces venezuelae#1i] ISP5230, a chloramphenicol producer. [i#J Biol Chem#1i] 1995; [b#270#1b]: 27000-6.
399. Peschke U, Schmidt H, Zhang HZ [i#et al.#1i] Molecular characterization of the lincomycin-production gene cluster of [i#Streptomyces lincolnensis#1i] 78-11. [i#Mol Microbiol#1i] 1995; [b#16#1b]: 1137-56.
400. Guilfoile PG, Hutchinson CR. Sequence and transcriptional analysis of the [i#Streptomyces glaucescens tcmAR#1i] tetracenomycin C resistance and repressor gene loci. [i#J Bacteriol#1i] 1992; [b#174#1b]: 3651-8.
401. Neal RJ, Chater KF. Nucleotide sequence analysis reveals similarities between proteins determining methylenomycin A resistance in [i#Streptomyces#1i] and tetracycline resistance in eubacteria. [i#Gene#1i] 1987; [b#58#1b]: 229-41.
402. Caballero JL, Malpartida F, Hopwood DA. Transcriptional organization and regulation of an antibiotic export complex in the producing [i#Streptomyces#1i] culture. [i#Mol Gen Genet#1i] 1991; [b#228#1b]: 372-80.
403. Blanc V, Salah-Bey K, Folcher M [i#et al.#1i] Molecular characterization and transcriptional analysis of a multidrug resistance gene cloned from the pristinamycin-producing organism, [i#Streptomyces pristinaespiralis. Mol Microbiol#1i] 1995; [b#17#1b]: 989-99.
404. Tercero JA, Lacalle RA, Jimenez A. The [i#pur8#1i] gene from the [i#pur#1i] cluster of [i#Streptomyces alboniger#1i] encodes a highly hydrophobic polypeptide which confers resistance to puromycin. [i#Eur J Biochem#1i] 1993; [b#218#1b]: 963-71.
405. Aparicio JF, Fouces R, Mendes MV [i#et al.#1i] A complex multienzyme system encoded by five polyketide synthase genes is involved in the biosynthesis of the 26-membered polyene macrolide pimaricin in [i#Streptomyces natalensis. Chem Biol#1i] 2000; [b#7#1b]: 895-905.
406. Mendez C, Salas JA. ABC transporters in antibiotic-producing actinomycetes. [i#FEMS Microbiol Lett#1i] 1998; [b#158#1b]: 1-8.
407. Fierro JF, Hardisson C, Salas JA. Resistance to oleandomycin in [i#Streptomyces antibioticus#1i], the producer organism. [i#J Gen Microbiol#1i] 1987; [b#133#1b]: 1931-9.
408. Sheridan RP, Chopra I. Origin of tetracycline efflux proteins: conclusions from nucleotide sequence analysis. [i#Mol Microbiol#1i] 1991; [b#5#1b]: 895-900.
409. Grkovic S, Brown MH, Skurray RA. Regulation of bacterial drug export systems. [i#Microbiol Mol Biol Rev#1i] 2002; [b#66#1b]: 671-701.
410. Matsuo Y, Eda S, Gotoh N [i#et al.#1i] MexZ-mediated regulation of [i#mexXY#1i] multidrug efflux pump expression in [i#Pseudomonas aeruginosa#1i] by binding on the [i#mexZ-mexX#1i] intergenic DNA. [i#FEMS Microbiol Lett#1i] 2004; [b#238#1b]: 23-8.
411. Morita Y, Komori Y, Mima T [i#et al.#1i] Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from [i#Pseudomonas aeruginosa#1i] PAO1: MexCD-OprJ is an inducible pump. [i#FEMS Microbiol Lett#1i] 2001; [b#202#1b]: 139-43.
412. Ma D, Cook DN, Alberti M [i#et al.#1i] Genes [i#acrA#1i] and [i#acrB#1i] encode a stress-induced system of [i#Escherichia coli. Mol Microbiol#1i] 1995; [b#16#1b]: 45-55.
413. Rosenberg EY, Bertenthal D, Nilles ML [i#et al.#1i] Bile salts and fatty acids induce the expression of [i#Escherichia coli#1i] AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. [i#Mol Microbiol#1i] 2003; [b#48#1b]: 1609-19.
414. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts in [i#Escherichia coli. J Bacteriol#1i] 1997; [b#179#1b]: 2512-8.
415. Shafer WM, Balthazar JT, Hagman KE [i#et al.#1i] Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of [i#Neisseria gonorrhoeae#1i] that are resistant to fecal lipids. [i#Microbiology#1i] 1995; [b#141#1b]: 907-11.
416. Hagman KE, Pan W, Spratt BG [i#et al.#1i] Resistance of [i#Neisseria gonorrhoeae#1i] to antimicrobial hydrophobic agents is modulated by the [i#mtrRCDE#1i] efflux system. [i#Microbiology#1i] 1995; [b#141#1b]: 611-22.
417. Lin J, Sahin O, Michel LO [i#et al.#1i] Critical role of multidrug efflux pump CmeABC in bile resistance and [i#in vivo#1i] colonization of [i#Campylobacter jejuni. Infect Immun#1i] 2003; [b#71#1b]: 4250-9.
418. Prouty AM, Brodsky IE, Falkow S [i#et al.#1i] Bile-salt-mediated induction of antimicrobial and bile resistance in [i#Salmonella typhimurium. Microbiology#1i] 2004; [b#150#1b]: 775-83.
419. Chatterjee A, Chaudhuri S, Saha G [i#et al.#1i] Effect of bile on the cell surface permeability barrier and efflux system of [i#Vibrio cholerae. J Bacteriol#1i] 2004; [b#186#1b]: 6809-14.
420. Nagakubo S, Nishino K, Hirata T [i#et al.#1i] The putative response regulator BaeR stimulates multidrug resistance of [i#Escherichia coli#1i] via a novel multidrug exporter system, MdtABC. [i#J Bacteriol#1i] 2002; [b#184#1b]: 4161-7.
421. Poole K. Bacterial multidrug resistance - emphasis on efflux mechanisms and [i#Pseudomonas aeruginosa. J Antimicrob Chemother#1i] 1994; [b#34#1b]: 453-6.
422. Helling RB, Janes BK, Kimball H [i#et al.#1i] Toxic waste disposal in [i#Escherichia coli. J Bacteriol#1i] 2002; [b#184#1b]: 3699-703.
423. Palumbo JD, Kado CI, Phillips DA. An isoflavonoid-inducible efflux pump in [i#Agrobacterium tumefaciens#1i] is involved in competitive colonization of roots. [i#J Bacteriol#1i] 1998; [b#180#1b]: 3107-13.
424. Burse A, Weingart H, Ullrich MS. The phytoalexin-inducible multidrug efflux pump AcrAB contributes to virulence in the fire blight pathogen, [i#Erwinia amylovora. Mol Plant Microbe Interact#1i] 2004; [b#17#1b]: 43-54.
425. Koretke KK, Lupas AN, Warren PV [i#et al.#1i] Evolution of two-component signal transduction. [i#Mol Biol Evol#1i] 2000; [b#17#1b]: 1956-70.
426. Li X-Z, Zhang L, Poole K. SmeC, an outer membrane multidrug efflux protein of [i#Stenotrophomonas maltophilia. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 333-43.
427. Baranova N, Nikaido H. The BaeSR two-component regulatory system activates transcription of the [i#yegMNOB (mdtABCD)#1i] transporter gene cluster in [i#Escherichia coli#1i] and increases its resistance to novobiocin and deoxycholate. [i#J Bacteriol#1i] 2002; [b#184#1b]: 4168-76.
428. Eguchi Y, Oshima T, Mori H [i#et al.#1i] Transcriptional regulation of drug efflux genes by EvgAS, a two-component system in [i#Escherichia coli. Microbiology#1i] 2003; [b#149#1b]: 2819-28.
429. Marchand I, Damier-Piolle L, Courvalin P [i#et al.#1i] Expression of the RND-type efflux pump AdeABC in [i#Acinetobacter baumannii#1i] is regulated by the AdeRS two-component system. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3298-304.
430. Lee LJ, Barrett JA, Poole RK. Genome-wide transcriptional response of chemostat-cultured [i#Escherichia coli#1i] to zinc. [i#J Bacteriol#1i] 2005; [b#187#1b]: 1124-34.
431. Cao L, Srikumar R, Poole K. MexAB-OprM hyperexpression in NalC type multidrug resistant [i#Pseudomonas aeruginosa#1i]: Identification and characterization of the [i#nalC#1i] gene encoding a repressor of PA3720-PA3719. [i#Mol Microbiol#1i] 2004; [b#53#1b]: 1423-36.
432. Sobel ML, Hocquet D, Cao L [i#et al.#1i] Mutations in PA3574 [i#(nalD #1i] lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of [i#Pseudomonas aeruginosa. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1782-6.
433. Hirakata Y, Srikumar R, Poole K [i#et al.#1i] Multidrug efflux systems play an important role in the invasiveness of [i#Pseudomonas aeruginosa. J Exp Med#1i] 2002; [b#196#1b]: 109-18.
434. Sanchez P, Linares JF, Ruiz-Diez B [i#et al.#1i] Fitness of [i#in vitro#1i] selected [i#Pseudomonas aeruginosa nalB#1i] and [i#nfxB#1i] multidrug resistant mutants. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 657-64.
435. Join-Lambert OF, Michea-Hamzehpour M, Kohler T [i#et al.#1i] Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of [i#Pseudomonas aeruginosa#1i] acute pneumonia in rats. [i#Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 571-6.
436. Alonso A, Morales G, Escalante R [i#et al.#1i] Overexpression of the multidrug efflux pump SmeDEF impairs [i#Stenotrophomonas maltophilia#1i] physiology. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 432-4.
437. Maseda H, Saito K, Nakajima A [i#et al.#1i] Variation of the [i#mexT#1i] gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of [i#Pseudomonas aeruginosa. FEMS Microbiol Lett#1i] 2000; [b#192#1b]: 107-12.
438. Sharma KG, Kaur R, Bachhawat AK. The glutathione-mediated detoxification pathway in yeast: An analysis using the red pigment that accumulates in certain adenine biosynthetic mutants of yeasts reveals the involvement of novel genes. [i#Arch Microbiol#1i] 2003; [b#180#1b]: 108-17.
439. Livshits VA, Zakataeva NP, Aleshin VV [i#et al.#1i] Identification and characterization of the new gene [i#rhtA#1i] involved in threonine and homoserine efflux in [i#Escherichia coli. Res Microbiol#1i] 2003; [b#154#1b] 123-35.
440. Yen MR, Tseng YH, Simic P [i#et al.#1i] The ubiquitous ThrE family of putative transmembrane amino acid efflux transporters. [i#Res Microbiol#1i] 2002; [b#153#1b]: 19-25.
441. Dassler T, Maier T, Winterhalter C [i#et al.#1i] Identification of a major facilitator protein from [i#Escherichia coli#1i] involved in efflux of metabolites of the cysteine pathway. [i#Mol Microbiol#1i] 2000; [b#36#1b] 1101-12.
442. Bellmann A, Vrljic M, Patek M [i#et al.#1i] Expression control and specificity of the basic amino acid exporter LysE of [i#Corynebacterium glutamicum. Microbiology#1i] 2001; [b#147#1b]: 1765-74.
443. Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of [i#Pseudomonas aeruginosa. J Bacteriol#1i] 1993; [b#175#1b]: 7793-800.
444. Frisk A, Schurr JR, Wang G [i#et al.#1i] Transcriptome analysis of [i#Pseudomonas aeruginosa#1i] after interaction with human airway epithelial cells. [i#Infect Immun#1i] 2004; [b#72#1b]: 5433-8.
445. Juhas M, Wiehlmann L, Huber B [i#et al.#1i] Global regulation of quorum sensing and virulence by VqsR in [i#Pseudomonas aeruginosa. Microbiology#1i] 2004; [b#150#1b]: 831-41.
446. Cosson P, Zulianello L, Join-Lambert O [i#et al. Pseudomonas aeruginosa#1i] virulence analyzed in a [i#Dictyostelium discoideum#1i] host system. [i#J Bacteriol#1i] 2002; [b#184#1b]: 3027-33.
447. Linares JF, Lopez JA, Camafeita E [i#et al.#1i] Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-oprN is associated with a reduction of type III secretion in [i#Pseudomonas aeruginosa. J Bacteriol#1i] 2005; [b#187#1b]: 1384-91.
448. Ramsey MM, Whiteley M. [i#Pseudomonas aeruginosa#1i] attachment and biofilm development in dynamic environments. [i#Mol Microbiol#1i] 2004; [b#53#1b]: 1075-87.
449. Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 2755-64.
450. Ince D, Zhang X, Silver LC [i#et al.#1i] Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3370-80.
451. Ince D, Zhang X, Silver LC [i#et al.#1i] Topoisomerase targeting with and resistance to gemifloxacin in [i#Staphylococcus aureus. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 274-82.
452. Kerns RJ, Rybak MJ, Kaatz GW [i#et al.#1i] Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of [i#Staphylococcus aureus. Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 1745-9.
453. Jacobs MR, Bajaksouzian S, Windau A [i#et al. In vitro#1i] activity of the new quinolone WCK 771 against staphylococci. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 3338-42.
454. Patel MV, De Souza NJ, Gupte SV [i#et al.#1i] Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 4754-61.
455. Azoulay-Dupuis E, Bedos JP, Mohler J [i#et al.#1i] Activities of garenoxacin against quinolone-resistant [i#Streptococcus pneumoniae#1i] strains [i#in vitro#1i] and in a mouse pneumonia model. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 765-73.
456. Grohs P, Houssaye S, Aubert A [i#et al. In vitro#1i] activities of garenoxacin (BMS-284756) against [i#Streptococcus pneumoniae#1i], viridans group streptococci, and [i#Enterococcus faecalis#1i] compared to those of six other quinolones. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 3542-7.
457. Zhanel GG, Hisanaga T, Nichol K [i#et al.#1i] Ketolides: An emerging treatment for macrolide-resistant respiratory infections, focusing on [i#Streptococcus pneumoniae. Expert Opin Emerg Drugs#1i] 2003; [b#8#1b]: 297-321.
458. Shortridge VD, Zhong P, Cao Z [i#et al.#1i] Comparison of [i#in vitro#1i] activities of ABT-773 and telithromycin against macrolide-susceptible and - resistant streptococci and staphylococci. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 783-6.
459. Hamilton-Miller JM, Shah S. Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant [i#Streptococcus pneumoniae#1i]: correlation with extended MLSK phenotypes. [i#J Antimicrob Chemother#1i] 2002; [b#50#1b]: 907-13.
460. Ono T, Kashimura M, Suzuki K [i#et al. In vitro#1i] and [i#in vivo#1i] antibacterial activities of the tricyclic ketolide TE-802 and its analogs. [i#J Antibiot (Tokyo)#1i] 2004; [b#57#1b]: 518-27.
461. Kozlov RS, Bogdanovitch TM, Appelbaum PC [i#et al.#1i] Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2963-8.
462. Reinert RR, Lutticken R, Bryskier A [i#et al.#1i] Macrolide-resistant [i#Streptococcus pneumoniae#1i] and [i#Streptococcus pyogenes#1i] in the pediatric population in Germany during 2000-2001. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 489-93.
463. Canton R, Mazzariol A, Morosini MI [i#et al.#1i] Telithromycin activity is reduced by efflux in [i#Streptococcus pyogenes. J Antimicrob Chemother#1i] 2005; [b#55#1b]: 489-95.
464. Hershberger E, Donabedian S, Konstantinou K [i#et al.#1i] Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. [i#Clin Infect Dis#1i] 2004; [b#38#1b]: 92-8.
465. Norcia LJ, Silvia AM, Santoro SL [i#et al. In vitro#1i] microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens. [i#J Antibiot (Tokyo)#1i] 2004; [b#57#1b]: 280-8.
466. Zhanel GG, Homenuik K, Nichol K [i#et al.#1i] The glycylcyclines: A comparative review with the tetracyclines. [i#Drugs#1i] 2004; [b#64#1b]: 63-88.
467. Hirata T, Saito A, Nishino K [i#et al.#1i] Effects of efflux transporter genes on susceptibility of [i#Escherichia coli#1i] to tigecycline (GAR-936). [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 2179-84.
468. Dean CR, Visalli MA, Projan SJ [i#et al.#1i] Efflux-mediated resistance to tigecycline (GAR-936) in [i#Pseudomonas aeruginosa#1i] PAO1. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 972-8.
469. Visalli MA, Murphy E, Projan SJ [i#et al.#1i] AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in [i#Proteus mirabilis. Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 665-9.
470. Ruzin A, Visalli MA, Keeney D [i#et al.#1i] Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in [i#Klebsiella pneumoniae. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1017-22.
471. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in [i#Morganella morganii. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 791-3.
472. McAleese F, Peterson P, Ruzin A [i#et al.#1i] A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived [i#Stophylococcus aureus#1i] mutants to tigecycline. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1865-71.
473. Li X, Zolli-Juran M, Cechetto JD [i#et al.#1i] Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. [i#Chem Biol#1i] 2004; [b#11#1b]: 1423-30.
474. Bozja J, Yi K, Shafer WM [i#et al.#1i] Porphyrin-based compounds exert antibacterial action against the sexually transmitted pathogens [i#Neisseria gonorrhoeae#1i] and [i#Haemophilus ducreyi. Int J Antimicrob Agents#1i] 2004; [b#24#1b]: 578-84.
475. Poole K. Overcoming multidrug resistance in Gram-negative bacteria. [i#Curr Opin Invest Drugs#1i] 2003; [b#4#1b]: 139.
476. Kaatz GW. Bacterial efflux pump inhibition. [i#Curr Opin Invest Drugs#1i] 2005; [b#6#1b]: 191-8.
477. Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 4171-6.
478. Stermitz FR, Cashman KK, Halligan KM [i#et al.#1i] Polyacylated neohesperidosides from [i#Geranium caespitosum#1i]: Bacterial multidrug resistance pump inhibitors. [i#Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 1915-8.
479. Guz NR, Stermitz FR, Johnson JB [i#et al.#1i] Flavonolignan and flavone inhibitors of a [i#Staphylococcus aureus#1i] multidrug resistance pump: structure-activity relationships. [i#J Med Chem#1i] 2001; [b#44#1b]: 261-8.
480. Stermitz FR, Beeson TD, Mueller PJ [i#et al. Staphylococcus aureus#1i] MDR efflux pump inhibitors from a [i#Berberis#1i] and a [i#Mahonia#1i] (sensu stricto) species. [i#Biochem Syst Ecol#1i] 2001; [b#29#1b]: 793-8.
481. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multidrug efflux pumps in [i#Staphylococcus aureus. J Antimicrob Chemother#1i] 2003; [b#51#1b] 13-7.
482. Kaatz GW, Moudgal VV, Seo SM [i#et al.#1i] Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in [i#Staphylococcus aureus. Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 254-61.
483. Belofsky G, Percivill D, Lewis K [i#et al.#1i] Phenolic metabolites of [i#Dalea versicolor#1i] that enhance antibiotic activity against model pathogenic bacteria. [i#J Natl Prod#1i] 2004; [b#67#1b]: 481-4.
484. Gibbons S, Moser E, Kaatz GW. Catechin gallates inhibit multidrug resistance (MDR) in [i#Staphylococcus aureus. Planta Med#1i] 2004; [b#70#1b] 1240-2.
485. Chopra I. New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors. [i#Drug Resist Updat#1i] 2002; [b#5#1b]: 119.
486. Gibbons S, Oluwatuyi M, Veitch NC [i#et al.#1i] Bacterial resistance modifying agents from [i#Lycopus europaeus. Phytochemistry#1i] 2003; [b#62#1b]: 83-7.
487. Fujita M, Shiota S, Kuroda T [i#et al.#1i] Remarkable synergies between baicalein and tetracycline, and baicalein and β-lactams against methicillin-resistant [i#Staphylococcus aureus. Microbiol Immunol#1i] 2005; [b#49#1b]: 391-6.
488. Oluwatuyi M, Kaatz GW, Gibbons S. Antibacterial and resistance modifying activity of [i#Rosmarinus officinalis. Phytochemistry#1i] 2004; [b#65#1b]: 3249-54.
489. Payot S, Avrain L, Magras C [i#et al.#1i] Relative contribution of target gene mutation and efflux to fluoroquinolone and erythromycin resistance, in French poultry and pig isolates of [i#Campylobacter coli. Int J Antimicrob Agents#1i] 2004; [b#23#1b]: 468-72.
490. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. [i#J Mol Microbiol Biotechnol#1i] 2001; [b#3#1b]: 225-36.
491. Saenz Y, Ruiz J, Zarazaga M [i#et al.#1i] Effect of the efflux pump inhibitor Phe-Arg-β-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in [i#Escherichia coli#1i] isolates of different origin. [i#J Antimicrob Chemother#1i] 2004; [b#53#1b]: 544-5.
492. Sanchez P, Le U, Martinez JL. The efflux pump inhibitor Phe-Arg-β-naphthylamide does not abolish the activity of the [i#Stenotrophomonas maltophilia#1i] SmeDEF multidrug efflux pump. [i#J Antimicrob Chemother#1i] 2003; [b#51#1b]: 1042-5.
493. Nakayama K, Kuru N, Ohtsuka M [i#et al.#1i] MexAB-OprM specific efflux pump inhibitors in [i#Pseudomonas aeruginosa#1i]. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety. [i#Bioorg Med Chem Lett#1i] 2004; [b#14#1b]: 2493-7.
494. Renau TE, Leger R, Filonova L [i#et al.#1i] Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in [i#Pseudomonas aeruginosa. Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 2755-8.
495. Nakayama K, Kawato H, Watanabe J [i#et al.#1i] MexAB-OprM specific efflux pump inhibitors in [i#Pseudomonas aeruginosa#1i]. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model. [i#Bioorg Med Chem Lett#1i] 2004; [b#14#1b]: 475-9.
496. Nakayama K, Ishida Y, Ohtsuka M [i#et al.#1i] MexAB-OprM specific efflux pump inhibitors in [i#Pseudomonas aeruginosa#1i]. Part 2: Achieving activity [i#in vivo#1i] through the use of alternative scaffolds. [i#Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 4205-8.
497. Nakayama K, Ishida Y, Ohtsuka M [i#et al.#1i] MexAB-OprM-specific efflux pump inhibitors in [i#Pseudomonas aeruginosa#1i]. Part 1: Discovery and early strategies for lead optimization. [i#Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 4201-4.
498. Watkins WJ, Landaverry Y, Leger R [i#et al.#1i] The relationship between physicochemical properties, [i#in vitro#1i] activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors. [i#Bioorg Med Chem Lett#1i] 2003; [b#13#1b]: 4241-4.
499. Renau TE, Leger R, Yen R [i#et al.#1i] Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in [i#Pseudomonas aeruginosa. Bioorg Med Chem Lett#1i] 2002; [b#12#1b]: 763-6.
500. Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in [i#Escherichia coli#1i] overexpressing RND efflux pumps. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 849-52.
501. Gallo S, Chevalier J, Mahamoud A [i#et al.#1i] 4-alkoxy and 4-thioalkoxyquinoline derivatives as chemosensitizers for the chloramphenicol-resistant clinical [i#Enterobacter aerogenes#1i] 27 strain. [i#Int J Antimicrob Agents#1i] 2003; [b#22#1b]: 270-3.
502. Mallea M, Mahamoud A, Chevalier J [i#et al.#1i] Alkylaminoquinolines inhibit the bacterial antibiotic efflux pump in multidrug-resistant clinical isolates. [i#Biochem J#1i] 2003; [b#376#1b]: 801-5.
503. Chevalier J, Atifi S, Eyraud A [i#et al.#1i] New pyridoquinoline derivatives as potential inhibitors of the fluoroquinolone efflux pump in resistant [i#Enterobacter aerogenes#1i] strains. [i#J Med Chem#1i] 2001; [b#44#1b]: 4023-6.
504. Chevalier J, Bredin J, Mahamoud A [i#et al.#1i] Inhibitors of antibiotic efflux in resistant [i#Enterobacter aerogenes#1i] and [i#Klebsiella pneumoniae#1i] strains. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 1043-6.
505. Poole K. Uninhibited antibiotic target discovery via chemical genetics. [i#Nat Biotechnol#1i] 2004; [b#22#1b]: 1528-9.
506. Tegos G, Stermitz FR, Lomovskaya O [i#et al.#1i] Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3133-41.
507. Chami M, Steinfels E, Orelle C [i#et al.#1i] Three-dimensional structure by cryo-electron microscopy of YvcC, an homodimeric ATP-binding cassette transporter from [i#Bacillus subtilis. J Mol Biol#1i] 2002; [b#315#1b]: 1075-85.
508. Ecker GF, Pleban K, Kopp S [i#et al.#1i] A three-dimensional model for the substrate binding domain of the multidrug ATP binding cassette transporter LmrA. [i#Mol Pharmacol#1i] 2004; [b#66#1b]: 1169-79.
509. Pleban K, Macchiarulo A, Costantino G [i#et al.#1i] Homology model of the multidrug transporter LmrA from [i#Lactococcus lactis. Bioorg Med Chem Lett#1i] 2004; [b#14#1b]: 5823-6.
510. Ubarretxena-Belandia I, Tate CG. New insights into the structure and oligomeric state of the bacterial multidrug transporter EmrE: An unusual asymmetric homo-dimer. [i#FEBS Lett#1i] 2004; [b#564#1b]: 234-8.
511. Ma C, Chang G. Structure of the multidrug resistance efflux transporter EmrE from [i#Escherichia coli. Proc Natl Acad Sci USA#1i] 2004; [b#101#1b] 2852-7.
512. Eswaran J, Koronakis E, Higgins MK [i#et al.#1i] Three's company: component structures bring a closer view of tripartite drug efflux pumps. [i#Curr Opin Struct Biol#1i] 2004; [b#14#1b]: 741-7.
513. Murakami S, Yamaguchi A. Multidrug-exporting secondary transporters. [i#Curr Opin Struct Biol#1i] 2003; [b#13#1b]: 443-52.
514. Akama H, Kanemaki M, Yoshimura M [i#et al.#1i] Crystal structure of the drug-discharge outer membrane protein, OprM, of [i#Pseudomonas aeruginosa#1i]: Dual modes of membrane anchoring and occluded cavity end. [i#J Biol Chem#1i] 2004; [b#17#1b]: 52816-9.
515. Higgins MK, Eswaran J, Edwards P [i#et al.#1i] Structure of the ligand-blocked periplasmic entrance of the bacterial multidrug efflux protein TolC. [i#J Mol Biol#1i] 2004; [b#342#1b]: 697-702.
516. Fernandez-Recio J, Walas F, Federici L [i#et al.#1i] A model of a transmembrane drug-efflux pump from Gram-negative bacteria. [i#FEBS Lett#1i] 2004; [b#578#1b]: 5-9.
517. Pos KM, Schiefner A, Seeger MA [i#et al.#1i] Crystallographic analysis of AcrB. [i#FEBS Lett#1i] 2004; [b#564#1b]: 333-9.
518. Gerken H, Misra R. Genetic evidence for functional interactions between TolC and AcrA proteins of a major antibiotic efflux pump of [i#Escherichia coli. Mol Microbiol#1i] 2004; [b#54#1b]: 620-31.
519. Husain F, Humbard M, Misra R. Interaction between the TolC and AcrA proteins of a multidrug efflux system of [i#Escherichia coli. J Bacteriol#1i] 2004; [b#186#1b]: 8533-6.
520. Elkins CA, Nikaido H. Chimeric analysis of AcrA function reveals the importance of its C-terminal domain in its interaction with the AcrB multidrug efflux pump. [i#J Bacteriol#1i] 2003; [b#185#1b]: 5349-56.
521. Touze T, Eswaran J, Bokma E [i#et al.#1i] Interactions underlying assembly of the [i#Escherichia coli#1i] AcrAB-TolC multidrug efflux system. [i#Mol Microbiol#1i] 2004; [b#53#1b]: 697-706.
522. Tikhonova EB, Zgurskaya HI. AcrA, AcrB, and TolC of [i#Escherichia coli#1i] form a stable intermembrane multidrug efflux complex. [i#J Biol Chem#1i] 2004; [b#279#1b]: 32116-24.
523. Nehme D, Li XZ, Elliot R [i#et al.#1i] Assembly of the MexAB-OprM multidrug efflux system of [i#Pseudomonas aeruginosa#1i]: Identification and characterization of mutations in [i#mexA#1i] compromising MexA multimerization and interaction with MexB. [i#J Bacteriol#1i] 2004; [b#186#1b]: 2973-83.
524. Mokhonov VV, Mokhonova EI, Akama H [i#et al.#1i] Role of the membrane fusion protein in the assembly of resistance-nodulation-cell division multidrug efflux pump in [i#Pseudomonas aeruginosa. Biochem Biophys Res Commun#1i] 2004; [b#322#1b]: 483-9.
525. Adler J, Bibi E. Determinants of substrate recognition by the [i#Escherichia coli#1i] multidrug transporter MdfA identified on both sides of the membrane. [i#J Biol Chem#1i] 2004; [b#279#1b]: 8957-65.
526. Adler J, Lewinson O, Bibi E. Role of a conserved membrane-embedded acidic residue in the multidrug transporter MdfA. [i#Biochemistry#1i] 2004; [b#43#1b]: 518-25.
527. Adler J, Bibi E. Promiscuity in the geometry of electrostatic interactions between the [i#Escherichia coli#1i] multidrug resistance transporter MdfA and cationic substrates. [i#J Biol Chem#1i] 2005; [b#280#1b] 2721-9.
528. Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of [i#Escherichia coli#1i]: Composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. [i#J Bacteriol#1i] 2003; [b#185#1b]: 5657-64.
529. McKeegan KS, Borges-Walmsley MI, Walmsley AR. Structural understanding of efflux-mediated drug resistance: Potential routes to efflux inhibition. [i#Curr Opin Pharmacol#1i] 2004; [b#4#1b]: 479-86.
530. Kobayashi N, Nishino K, Yamaguchi A. Novel macrolide-specific ABC-type efflux transporter in [i#Escherichia coli. J Bacteriol#1i] 2001; [b#183#1b] 5639-44.
531. Roberts MC. Tetracycline resistance determinants: Mechanisms of action, regulation of expression, genetic mobility, and distribution. [i#FEMS Microbiol Lett#1i] 1996; [b#19#1b]: 1-24.
532. Rosenberg EY, Ma D, Nikaido H. AcrD of [i#Escherichia coli#1i] is an aminoglycoside efflux pump. [i#J Bacteriol#1i] 2000; [b#182#1b]: 1754-6.
533. Moore RA, DeShazer D, Reckseidler S [i#et al.#1i] Efflux-mediated aminoglycoside and macrolide resistance in [i#Burkholderia pseudomallei. Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 465-70.
534. Yoshida H, Bogaki M, Nakamura S [i#et al.#1i] Nucleotide sequence and characterization of the [i#Staphylococcus aureus norA#1i] gene, which confers resistance to quinolones. [i#J Bacteriol#1i] 1990; [b#172#1b]: 6942-9.
535. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, [i#pmrA#1i], associated with fluoroquinolone resistance in [i#Streptococcus pneumoniae. Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 187-9.
536. Price LB, Vogler A, Pearson T [i#et al. In vitro#1i] selection and characterization of [i#Bacillus anthracis#1i] mutants with high-level resistance to ciprofloxacin. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 2362-5.
537. Ohki R, Murata M. [i#bmr3#1i], a third multidrug transporter gene of [i#Bacillus subtilis. J Bacteriol#1i] 1997; [b#179#1b]: 1423-7.
538. Liu J, Takiff HG, Nikaido H. Active efflux of fluoroquinolones in [i#Mycobacterium smegmatis#1i] mediated by LfrA, a multidrug efflux pump. [i#J Bacteriol#1i] 1996; [b#178#1b]: 3791-5.
539. Pradel E, Pages JM. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen [i#Enterobacter aerogenes. Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 2640-3.
540. Schneiders T, Amyes SG, Levy SB. Role of AcrR and RamA in fluoroquinolone resistance in clinical [i#Klebsiella pneumoniae#1i] isolates from Singapore. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b] 2831-7.
541. Baucheron S, Imberechts H, Chaslus-Dancla E [i#et al.#1i] The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in [i#Salmonella enterica#1i] serovar typhimurium phage type DT204. [i#Microb Drug Resist#1i] 2002; [b#8#1b]: 281-9.
542. Alonso A, Martinez JL. Expression of multidrug efflux pump SmeDEF by clinical isolates of [i#Stenotrophomonas maltophilia. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 1879-81.
543. Valdezate S, Vindel A, Echeita A [i#et al.#1i] Topoisomerase II and IV quinolone resistance-determining regions in [i#Stenotrophomonas maltophilia#1i] clinical isolates with different levels of quinolone susceptibility. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 665-71.
544. Luo N, Sahin O, Lin J [i#et al. In vivo#1i] selection of [i#Campylobacter#1i] isolates with high levels of fluoroquinolone resistance associated with [i#gyrA#1i] mutations and the function of the CmeABC efflux pump. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 390-4.
545. Kumar A, Worobec EA. Cloning sequencing and characterization of the SdeAB multidrug efflux pump of [i#Serratia marcescens. Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1495-1501.
546. Tavio M, Vila J, Ruiz J [i#et al. In vitro#1i] selected fluoroquinolone-resistant mutants of [i#Citrobacter freundii#1i]: analysis of the quinolone resistance acquisition. [i#J Antimicrob Chemother#1i] 2000; [b#45#1b]: 521-4.
547. Navia MM, Ruiz J, Ribera A [i#et al.#1i] Analysis of the mechanisms of quinolone resistance in clinical isolates of [i#Citrobacter freundii. J Antimicrob Chemother#1i] 1999; [b#44#1b]: 743-8.
548. Ishii H, Sato K, Hoshino K [i#et al.#1i] Active efflux of ofloxacin by a highly quinolone-resistant strain of [i#Proteus vulgaris. J Antimicrob Chemother#1i] 1991; [b#28#1b]: 827-36.
549. Oh H, Edlund C. Mechanism of quinolone resistance in anaerobic bacteria. [i#Clin Microbiol Infect#1i] 2003; [b#9#1b]: 512-7.
550. Miyamae S, Ueda O, Yoshimura F [i#et al.#1i] A MATE family multidrug efflux transporter pumps out fluoroquinolones in [i#Bacteroides thetaiotaomicron. Antimicrob Agents Chemother#1i] 2001; [b#45#1b]: 3341-6.
551. Burse A, Weingart H, Ullrich MS. NorM, an [i#Erwinia amylovora#1i] multidrug efflux pump involved in [i#in vitro#1i] competition with other epiphytic bacteria. [i#Appl Environ Microbiol#1i] 2004; [b#70#1b]: 693-703.
552. Morita Y, Kodama K, Shiota S [i#et al.#1i] NorM, a putative multidrug efflux protein, of [i#Vibrio parahaemolyticus#1i] and its homolog in [i#Escherichia coli. Antimicrob Agents Chemother#1i] 1998; [b#42#1b]: 1778-82.
553. Rouquette-Loughlin C, Dunham SA, Kuhn M [i#et al.#1i] The NorM efflux pump of [i#Neisseria gonorrhoeae#1i] and [i#Neisseria meningitidis#1i] recognizes antimicrobial cationic compounds. [i#J Bacteriol#1i] 2003; [b#185#1b]: 1101-6.
554. Xu XJ, Su XZ, Morita Y [i#et al.#1i] Molecular cloning and characterization of the HmrM multidrug efflux pump from [i#Haemophilus influenzae#1i] Rd. [i#Microbiol Immunol#1i] 2003; [b#47#1b]: 937-43.
555. +-coupled multidrug efflux pump, PmpM, a member of the MATE family of transporters, from [i#Pseudomonas aeruginosa. J Bacteriol#1i] 2004; [b#186#1b]: 262-5.
556. Dridi L, Tankovic J, Petit JC. CdeA of [i#Clostridium difficile#1i], a new multidrug efflux transporter of the MATE family. [i#Microb Drug Resist#1i] 2004; [b#10#1b]: 191-6.
557. Brown MH, Skurray RA. Staphylococcal multidrug efflux protein QacA. [i#J Mol Microbiol Biotechnol#1i] 2001; [b#3#1b]: 163-70.
558. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. [i#Clin Microbiol Rev#1i] 1999; [b#12#1b]: 147-79.
559. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. [i#Microbiol Rev#1i] 1996; [b#60#1b]: 575-608.
560. Littlejohn TG, Paulsen IT, Gillespie MT [i#et al.#1i] Substrate specificity and energetics of antiseptic and disinfectant resistance in [i#Staphylococcus aureus. FEMS Microbiol Lett#1i] 1992; [b#74#1b]: 259-65.
561. Sasatsu M, Shirai Y, Hase M [i#et al.#1i] The origin of the antiseptic-resistance gene [i#ebr#1i] in [i#Staphylococcus aureus. Microbios#1i] 1995; [b#84#1b]: 161-9.
562. Heir E, Sundheim G, Holck AL. The [i#qacG#1i] gene on plasmid pST94 confers resistance to quaternary ammonium compounds in staphylococci isolated from the food industry. [i#J Appl Microbiol#1i] 1999; [b#86#1b]: 378-88.
563. Heir E, Sundheim G, Holck AL. The [i#Staphylococcus aureus qacH#1i] gene product: A new member of the SMR family encoding multidrug resistance. [i#FEMS Microbiol Lett#1i] 1998; [b#163#1b]: 49-56.
564. Paulsen IT, Littlejohn TG, Radstrom P [i#et al.#1i] The 3′ conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and disinfectants. [i#Antimicrob Agents Chemother#1i] 1993; [b#37#1b]: 761-8.
565. Kazama H, Hamashima H, Sasatsu M [i#et al.#1i] Distribution of the antiseptic-resistance genes [i#qacE#1i] and [i#qacEΔ1#1i] in gram-negative bacteria. [i#FEMS Microbiol Lett#1i] 1998; [b#159#1b]: 173-8.
566. Kazama H, Hamashima H, Sasatsu M [i#et al.#1i] Characterization of the antiseptic-resistance gene [i#qacEΔ1#1i] isolated from clinical and environmental isolates of [i#Vibrio parahaemolyticus#1i] and [i#Vibrio cholerae#1i] non-O1. [i#FEMS Microbiol Lett#1i] 1999; [b#174#1b]: 379-84.
567. Daly M, Fanning S. Integron analysis and genetic mapping of antimicrobial resistance genes in [i#Salmonella enterica#1i] serotype Typhimurium. [i#Methods Mol Biol#1i] 2004; [b#268#1b]: 15-32.
568. Bass L, Liebert CA, Lee MD [i#et al.#1i] Incidence and characterization of integrons, genetic elements mediating multiple-drug resistance, in avian [i#Escherichia coli. Antimicrob Agents Chemother#1i] 1999; [b#43#1b] 2925-9.
569. Barlow RS, Pemberton JM, Desmarchelier PM [i#et al.#1i] Isolation and characterization of integron-containing bacteria without antibiotic selection. [i#Antimicrob Agents Chemother#1i] 2004; [b#48#1b]: 838-42.
570. Ploy MC, Courvalin P, Lambert T. Characterization of In40 of [i#Enterobacter aerogenes#1i] BM2688, a class 1 integron with two new gene cassettes, [i#cmlA2#1i] and [i#qacF. Antimicrob Agents Chemother#1i] 1998; [b#42#1b]: 2557-63.
571. Plante I, Centron D, Roy PH. Direct sequencing and PCR mapping of integrons reveals multiple class 1 integrons in the multiresistant strain [i#Enterobacter cloacae#1i] SCH88040794. [i#FEMS Microbiol Lett#1i] 2003;[b#221#1b]:59-62.
572. MP-containing [i#Pseudomonas aeruginosa#1i] integron phyletically related to In5, which carries an unusual array of gene cassettes. [i#Antimicrob Agents Chemother#1i] 1999; [b#43#1b]: 890-901.
573. L'Abee-Lund TM, Sorum H. Class 1 integrons mediate antibiotic resistance in the fish pathogen [i#Aeromonas salmonicida#1i] worldwide. [i#Microb Drug Resist#1i] 2001; [b#7#1b]: 263-72.
574. Nishino K, Yamaguchi A. EvgA of the two-component signal transduction system modulates production of the YhiUV multidrug transporter in [i#Escherichia coli. J Bacteriol#1i] 2002; [b#184#1b]: 2319-23.
575. Edgar R, Bibi E. MdfA, an [i#Escherichia coli#1i] multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. [i#J Bacteriol#1i] 1997; [b#179#1b]: 2274-80.
576. Chung YJ, Saier MH, Jr. Overexpression of the [i#Escherichia coli sugE#1i] gene confers resistance to a narrow range of quaternary ammonium compounds. [i#J Bacteriol#1i] 2002; [b#184#1b]: 2543-5.
577. Schweizer HP. Intrinsic resistance to inhibitors of fatty acid biosynthesis in [i#Pseudomonas aeruginosa#1i] is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. [i#Antimicrob Agents Chemother#1i] 1998; [b#42#1b]: 394-8.
578. Gupta A, Matsui K, Lo JF [i#et al.#1i] Molecular basis for resistance to silver cations in [i#Salmonella. Nat Med#1i] 1999; [b#5#1b]: 183-8.